107 results on '"Lionel Groussin"'
Search Results
2. SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules : Role of molecular tests for cytologically indeterminate thyroid nodules
- Author
-
Hélène Lasolle, Jonathan Lopez, François Pattou, Françoise Borson-Chazot, Stéphane Bardet, Lionel Groussin, and Camille Buffet
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
3. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients
- Author
-
Fidéline Bonnet-Serrano, Jonathan Poirier, Anna Vaczlavik, Christelle Laguillier-Morizot, Benoît Blanchet, Stéphanie Baron, Laurence Guignat, Laura Bessiene, Léopoldine Bricaire, Lionel Groussin, Guillaume Assié, Jean Guibourdenche, and Jérôme Bertherat
- Subjects
Hydrocortisone ,Pyridines ,Endocrinology, Diabetes and Metabolism ,Cortodoxone ,Androstenedione ,Imidazoles ,General Medicine ,Metyrapone ,Endocrinology ,Adrenocorticotropic Hormone ,Tandem Mass Spectrometry ,Humans ,Steroid 11-beta-Hydroxylase ,Female ,Testosterone ,Steroid 21-Hydroxylase ,Cushing Syndrome ,Chromatography, Liquid - Abstract
Introduction Osilodrostat is a new 11β-hydroxylase inhibitor with a mode of action analogous to Metyrapone. The objective of this study was to compare steroidogenic profiles in patients treated with either Osilodrostat or Metyrapone for adrenocorticotrophic hormone (ACTH)-dependent Cushing's syndrome (CS). Methods Patients followed up at Cochin hospital Endocrinology department between March 2019 and December 2021 for an ACTH-dependent CS, controlled by either Osilodrostat or Metyrapone, were included. A serum profile of five steroids (cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, androstenedione and testosterone) was determined using UPLC- tandem mass spectrometry (UPLC-MS/MS). Results Nineteen patients treated with Osilodrostat, eight patients treated with Metyrapone and six patients treated with consecutive Metyrapone then Osilodrostat were included. Hypocortisolism (basal cortisol Conclusion In patients with ACTH-dependent CS, the use of CYP11B1 inhibitors in routine care suggests that Osilodrostat has a less specific effect on the inhibition of steroidogenic enzymes than Metyrapone. This might explain a smaller increase in 11-deoxycortisol and androgen levels in patients treated with Osilodrostat.
- Published
- 2022
- Full Text
- View/download PDF
4. Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer
- Author
-
Lionel Groussin, Hélène Theodon, Laura Bessiene, Leopoldine Bricaire, Fidéline Bonnet-Serrano, Béatrix Cochand-Priollet, Karen Leroy, Simon Garinet, Eric Pasmant, Jérémie Zerbit, Romain Seban, François Goldwasser, Jérôme Clerc, Anne Segolene Cottereau, and Olivier Huillard
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism - Published
- 2022
- Full Text
- View/download PDF
5. Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients
- Author
-
Lucas Bouys, Anna Vaczlavik, Anne Jouinot, Patricia Vaduva, Stéphanie Espiard, Guillaume Assié, Rossella Libé, Karine Perlemoine, Bruno Ragazzon, Laurence Guignat, Lionel Groussin, Léopoldine Bricaire, Isadora Pontes Cavalcante, Fidéline Bonnet-Serrano, Hervé Lefebvre, Marie-Laure Raffin-Sanson, Nicolas Chevalier, Philippe Touraine, Christel Jublanc, Camille Vatier, Gérald Raverot, Magalie Haissaguerre, Luigi Maione, Matthias Kroiss, Martin Fassnacht, Sophie Christin-Maitre, Eric Pasmant, Françoise Borson-Chazot, Antoine Tabarin, Marie-Christine Vantyghem, Martin Reincke, Peter Kamenicky, Marie-Odile North, Jérôme Bertherat, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Lille, Recherche translationnelle sur le diabète - U 1190 (RTD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Rouen, Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hospices Civils de Lyon (HCL), Hôpital Haut-Lévêque - CHU de Bordeaux (Centre médico chirurgical Magellan), Physiologie et physiopathologie endocriniennes (PHYSENDO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), University Hospital of Würzburg, Klinikum der Universität [München], CHU Saint-Antoine [AP-HP], L B is recipient of research fellowships from the Cancer Research for Personalized Medicine (CARPEM) and the Fondation ARC pour la Recherche contre le Cancer, J B laboratory is supported by the Agence Nationale pour la Recherche grant ANR-18-CE14-0008-01 and the Fondation pour la Recherche Médicale (EQU201903007854). P T, C J, M F, S C M, F B C, M R, P C and J B clinical departments are part the European Reference Network on Rare Endocrine Conditions (Endo-ERN) – Project ID No 739572, and ANR-18-CE14-0008,STEROMICS,Steroïdogénomique de l'hypersécrétion des stéroïdes surrénaliens(2018)
- Subjects
Armadillo Domain Proteins ,Hyperplasia ,Hydrocortisone ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,71 ARMC5 ,General Medicine ,genetic screening ,PBMAH ,Endocrinology ,Primary Bilateral Macronodular Adrenal Hyperplasia ,adrenal tumors ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Adrenal Glands ,Humans ,Cushing syndrome ,tumor suppressor gene ,Retrospective Studies - Abstract
Objective Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a heterogeneous disease characterized by adrenal macronodules and variable levels of cortisol excess, with not clearly established clinical diagnostic criteria. It can be caused by ARMC5 germline pathogenic variants. In this study, we aimed to identify predictive criteria for ARMC5 variants. Methods We included 352 consecutive index patients from 12 European centers, sequenced for germline ARMC5 alteration. Clinical, biological and imaging data were collected retrospectively. Results 52 patients (14.8%) carried ARMC5 germline pathogenic variants and showed a more distinct phenotype than non-mutated patients for cortisol excess (24-h urinary free cortisol 2.32 vs 1.11-fold ULN, respectively, P < 0.001) and adrenal morphology (maximal adrenal diameter 104 vs 83 mm, respectively, P < 0.001) and were more often surgically or medically treated (67.9 vs 36.8%, respectively, P < 0.001). ARMC5-mutated patients showed a constant, bilateral adrenal involvement and at least a possible autonomous cortisol secretion (defined by a plasma cortisol after 1 mg dexamethasone suppression above 50 nmol/L), while these criteria were not systematic in WT patients (78.3%). The association of these two criteria holds a 100% sensitivity and a 100% negative predictive value for ARMC5 pathogenic variant. Conclusion We report the largest series of index patients investigated for ARMC5 and confirm that ARMC5 pathogenic variants are associated with a more severe phenotype in most cases. To minimize negative ARMC5 screening, genotyping should be limited to clear bilateral adrenal involvement and autonomous cortisol secretion, with an optimum sensitivity for routine clinical practice. These findings will also help to better define PBMAH diagnostic criteria.
- Published
- 2023
- Full Text
- View/download PDF
6. C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a single-center study of 159 fasting trials
- Author
-
Fidéline Bonnet-Serrano, Clara Devin-Genteuil, Louis Thomeret, Christelle Laguillier-Morizot, Marie-Clémence Leguy, Anna Vaczlavik, Lucas Bouys, Corinne Zientek, Léopoldine Bricaire, Laura Bessiène, Laurence Guignat, Rossela Libé, Helen Mosnier-Pudar, Guillaume Assié, Lionel Groussin, Jean Guibourdenche, and Jérôme Bertherat
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
IntroductionDiagnosis of endogenous hyperinsulinism relies on the occurrence of a hypoglycemia, concomitant with inadequate high insulin and C-peptide levels. However, diagnostic cutoffs are not consensual among the different learned societies. The objective of this work was to propose optimized cutoffs for these three parameters for the diagnosis of endogenous hyperinsulinism.MethodsAll the patients having performed a fasting trial in Cochin Hospital Endocrinology Department between February 2012 and August 2022 were included. The results of glycemia, insulin and C-peptide levels during fasting trial were collected and analyzed.ResultsOne hundred and fifty-nine patients were included: 26 with endogenous hyperinsulinism and 133 without endogenous hyperinsulinism. ROC analysis of glycemia nadir during fasting trial identified the value of 2.3 mmol/L as the optimal cutoff, ensuring a sensitivity of 100% associated with a specificity of 81%. ROC analysis of insulin and C-peptide levels concomitant with hypoglycemia ConclusionA C-peptide level 0.3 nmol/L concomitant with a hypoglycemia
- Published
- 2023
- Full Text
- View/download PDF
7. Atypical Presentation of Testicular Adrenal Rest Tumor (TART) Leading to Bilateral Partial Orchiectomy in a 31-Year-Old Adult Revealing Primary Adrenal Insufficiency with CYP11A1 Deficiency
- Author
-
Cyril Garcia, Marie Dusaud, Paul Chiron, Mathilde Sollier, Sika Nassouri, Lionel Groussin, Mathilde Sibony, Claire Goursaud, Florence Roucher-Boulez, and Lyse Bordier
- Subjects
Endocrinology, Diabetes and Metabolism ,Case Report ,RC648-665 ,Diseases of the endocrine glands. Clinical endocrinology - Abstract
Adrenogenital syndrome is commonly associated with a deficiency in 21-hydroxylase but can be present in other rare enzymatic blocks. We report here the case of a 31-year-old man who presented with bilateral painful testicle lesions leading to bilateral partial orchiectomy as they were suspected for malignancy. These lesions were finally identified as benign testicle adrenal rest tumors (TARTs), and the patient was actually belatedly diagnosed with primary adrenal insufficiency due to 2 mutations of the CYP11A1 gene encoding the cholesterol side-chain cleavage enzyme (P450scc); the mutations were 940G > A (p.Glu314Lys) and c.1393C > T (p.Arg465Trp). The same mutations were found in his 29-year-old sister, who was then also diagnosed for primary adrenal insufficiency. Deficiency in P450scc is an extremely rare genetic autosomal recessive disorder with around 40 described families in the literature and 30 different mutations. As the diagnosis of delayed onset of P450Scc mutation is difficult, this case illustrates the need for a systematic endocrinological assessment in any case of bilateral testicle lesions, thus avoiding unnecessary surgery.
- Published
- 2021
- Full Text
- View/download PDF
8. Noninvasive Prenatal Diagnosis of a Paternally Inherited MEN1 Pathogenic Splicing Variant
- Author
-
Thomas Huby, Edouard Le Guillou, Cyril Burin des Roziers, Laurence Pacot, Audrey Briand-Suleau, Albain Chansavang, Aurélie Toussaint, Véronique Duchossoy, Nicolas Vaucouleur, Virginie Benoit, Laurence Lodé, Clémence Molac, Marie-Odile North, Sarah Grotto, Vassilis Tsatsaris, Anne Jouinot, Béatrix Cochand-Priollet, Anne-Cécile Paepegaey, Juliette Nectoux, Lionel Groussin, and Eric Pasmant
- Subjects
Adult ,Male ,endocrine system diseases ,Hyperparathyroidism ,Noninvasive Prenatal Testing ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,Biochemistry ,Endocrinology ,Pregnancy ,Multiple Endocrine Neoplasia Type 1 ,Paternal Inheritance ,Humans ,Female ,Genetic Testing - Abstract
Context Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the tumor suppressor gene MEN1. The uncertainty of pathogenicity of MEN1 variants complexifies the selection of the patients likely to benefit from specific care. Objective MEN1-mutated patients should be offered tailored tumor screening and genetic counseling. We present a patient with hyperparathyroidism for whom genetic analysis identified a variant of uncertain significance in the MEN1 gene (NM_130799.2): c.654G > T p.(Arg218=). Additional functional genetic tests were performed to classify the variant as pathogenic and allowed prenatal testing. Design Targeted next generation sequencing identified a synonymous variant in the MEN1 gene in a 26-year-old male with symptomatic primary hyperparathyroidism. In silico and in vitro genetic tests were performed to assess variant pathogenicity. Results Genetic testing of the proband’s unaffected parents showed the variant occurred de novo. Transcript study showed a splicing defect leading to an in-frame deletion. The classification of the MEN1 variant as pathogenic confirmed the diagnosis of MEN1 and recommended an adapted medical care and follow-up. Pathogenic classification also allowed to propose a genetic counseling to the proband and his wife. Noninvasive prenatal diagnosis was performed with a personalized medicine-based protocol by detection of the paternally inherited variant in maternal plasmatic cell free DNA, using digital PCR. Conclusion We showed that functional genetic analysis can help to assess the pathogenicity of a MEN1 variant with crucial consequences for medical care and genetic counseling decisions.
- Published
- 2021
- Full Text
- View/download PDF
9. Decreased steroidogenic enzyme activity in benign adrenocortical tumors is more pronounced in bilateral lesions as determined by steroid profiling in LC-MS/MS during ACTH stimulation test
- Author
-
Fidéline Bonnet-Serrano, Maxime Barat, Anna Vaczlavik, Anne Jouinot, Lucas Bouys, Christelle Laguillier-Morizot, Corinne Zientek, Catherine Simonneau, Etienne Larger, Laurence Guignat, Lionel Groussin, Guillaume Assié, Jean Guibourdenche, Ioannis Nicolis, Marie-Claude Menet, and Jérôme Bertherat
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
Objective Large response of steroid precursors, including 17-hydroxyprogesterone, to adrenocorticotropic hormone (ACTH) has been described in adrenocortical tumors, suggesting the existence of intra-tumoral enzymatic deficiencies. This study aimed to compare steroidogenesis enzymes activity in unilateral and bilateral benign tumors using serum steroid profiling in liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the basal state and after ACTH 1-24 stimulation. Design and methods A serum profile of seven consecutive adrenal steroids was determined in LC-MS/MS in the basal state (T0) and after ACTH 1-24 stimulation (T60) in 35 patients with bilateral adrenocortical tumors (BL), 38 patients with unilateral tumors (UL) and 37 control subjects (CT). Response amplitude of each individual steroid was evaluated by T60/T0 ratio, whereas enzymatic activity was assessed by the downstream/upstream steroid ratio. Adrenal volume was quantified by a semi-automatic segmentation method. Results For the seven steroids assayed, the amplitude of response to ACTH was higher in BL than in UL and in CT. The difference between BL and UL persisted even after matching patients on adrenal volume. On glucocorticoids pathway, enzymatic activity of CYP11B1 was significantly decreased in BL (78.3 (43.1-199.4)) in comparison to both UL (122.7 (13.8-228.4), P = 0.0002) and CT (186.8 (42.1-1236.3), P Conclusions Decreased activity of distal steroidogenesis enzymes CYP11B1, CYP11B2 and CYP17A1-17,20 lyase, responsible for an explosive response to ACTH of upstream precursors in bilateral tumors, limits the synthesis of bioactive steroids, in particular cortisol, despite the increase in adrenal mass. Significance statement Activity of distal steroidogenesis enzymes (CYP11B1, CYP11B2 and CYP17A1 on glucocorticoids, mineralocorticoids and androgens pathways, respectively) is decreased in adrenocortical benign tumors. This decrease is more pronounced in bilateral lesions and seems to depend more on the nature of the lesion than on the increase in adrenal volume. It is responsible for the explosive response to ACTH of steroid precursors located upstream of these enzymes. It probably allows bioactive steroids, particularly cortisol, to stay in the normal range for a long time despite the increase in adrenal mass.
- Published
- 2022
- Full Text
- View/download PDF
10. Possible Primary Thyroid Nuclear Protein in Testis Carcinomas withiNSD3::NUTM1/iTranslocation Revealed by RNA Sequencing: A Report of Two Cases
- Author
-
Noémie Scherman, Johanna Wassermann, Camille Tlemsani, Erell Guillerm, Gabrielle Deniziaut, Beatrix Cochand-Priollet, Larrys Shan, Nathalie Chereau, Sébastien Gaujoux, Jean-Marc Simon, Laurence Leenhardt, Lionel Groussin, and Camille Buffet
- Subjects
Male ,Adult ,Endocrinology ,Sequence Analysis, RNA ,Endocrinology, Diabetes and Metabolism ,Testis ,Carcinoma ,Thyroid Gland ,Humans ,Nuclear Proteins ,Female ,Neoplasm Proteins - Abstract
biBackground:/i/bNuclear protein in testis (NUT) carcinomas (NC) are a rare, highly aggressive, subset of squamous cell carcinomas, characterized by a translocation involving theiNUTM1/igene. Thyroid location of NUT carcinomas has rarely been described.biMethods:/i/bWe report here two cases of thyroid NC withiNSD3::NUTM1/itranslocation.biResults:/i/bThe first case presented as a very aggressive undifferentiated thyroid carcinoma in a 38-year-old man who died 21 months after the diagnosis. The second case was diagnosed after multiple lymphadenopathy recurrences mainly in the neck in a 37-year-old woman 7 years after total thyroidectomy for papillary thyroid carcinoma with a classic and a solid/trabecular component.biConclusions:/i/bOur case reports highlight the challenges in diagnosing these exceptional carcinomas. The therapeutic impact of the administration of pharmacological compounds with epigenetic action, in line with the physiopathology of these carcinomas, is also discussed.
- Published
- 2022
11. Amiodarone-induced thyrotoxicosis
- Author
-
Lionel Groussin, Louis Schubert, and Léopoldine Bricaire
- Subjects
Pediatrics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Amiodarone ,030209 endocrinology & metabolism ,Disease ,Thyroid Function Tests ,History, 21st Century ,Amiodarone-induced thyrotoxicosis ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Hypothyroidism ,medicine ,business.industry ,Thyroid ,General Medicine ,Pathophysiology ,Thyrotoxicosis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,business ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians are sometimes faced with difficult diagnostic and therapeutic situations. The disease pathophysiology is partially understood, explaining the lack of predictive factors for occurrence. Different international recommendations for their management have been published: the most recent in 2018 by the European Thyroid Association (ETA) (Ross et al., 2016; Bartalena et al., 2018). The purpose of this paper is to present the essential concepts for their management and to review the literature since 2018.
- Published
- 2021
- Full Text
- View/download PDF
12. OR04-3 Genetic Alterations of ARMC5 and KDM1A Are Associated With Different Expression Profiles of Illegitimate Receptors in Primary Bilateral Macronodular Adrenal Hyperplasia
- Author
-
Roberta Armignacco, Guillaume Assié, Maxime Barat, Jérôme Bertherat, Annabel Berthon, Fidéline Bonnet-Serrano, Isadora P Cavalcante, Bertrand Dousset, Gaëtan Giannone, Lionel Groussin, Laurence Guignat, Anne Jouinot, Rossella Libé, Marie-Odile North, Eric Pasmant, Karine Perlemoine, Bruno Ragazzon, Christopher Ribes, Mathilde Sibony, Anna Vaczlavik, Patricia Vaduva, Florian Violon, and Lucas Bouys
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
Introduction Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH) is a heterogeneous disease characterized by bilateral adrenal macronodules responsible for adrenal Cushing. To date, two genetic causes of PBMAH are known: germline inactivating variants of the tumor suppressor genes ARMC5 identified in 2013 (Assié, N Eng J Med 2013), responsible for 20 to 25% of index cases, and KDM1A, identified recently (Vaczlavik, GIM 2021; Chasseloup, Lancet D&E 2021), responsible for the rare presentation associated with food-dependent Cushing's syndrome (FDCS) due to aberrant expression of the GIP receptor (GIPR) in adrenocortical cells. Multiple other illegitimate receptors are known to be responsible for abnormal cortisol response to various physiological stimuli in PBMAH. A recent multiomic analysis, identified three distinct molecular PBMAH groups: G1 with ARMC5-mutated tumors, G2 with KDM1A-mutated tumors from FDCS patients, and G3 with no identified genetic cause at present. We aimed to identify specific expression profiles of illegitimate receptors in the three groups. Methods Based on the transcriptome data obtained by RNA sequencing (Illumina) of the tumors from 31 patients (G1/ARMC5, 16 patients; G2/KDM1A, 6 patients; G3, 9 patients), expression of the following genes, encoding potential illegitimate receptors, were compared: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, AVPR1A, AVPR1B, AVPR2, GCGR, GIPR, HTR4, HTR7, LHCGR. Calculations were performed using R statistical software. The Bioconductor limma package was used to analyze mRNA differential expression. Results G1/ARMC5 tumors showed a relative overexpression of the vasopressin receptors AVPR1A and AVPR1B compared to the two other groups (fold-change [FC] =7.39, p Conclusion This study reveals specific expression profiles of illegitimate receptors related to the three molecular groups. ARMC5 tumors are associated with the overexpression of two vasopressin receptors, while, besides GIPR, KDM1A inactivation seems to drive the overexpression of the LH/hCG receptor, as previously suggested in patients with FDCS (Bertherat, JCE&M 2005), potentially responsible for Cushing's syndrome associated with pregnancy and menopause. These molecular patterns need to be corroborated by clinical data with a systematic testing of the aberrant cortisol responses. Additionally, further studies would be needed to investigate the clinical relevance and significance of moderate fold-changes in gene expression (e.g. Presentation: Saturday, June 11, 2022 12:00 p.m. - 12:15 p.m.
- Published
- 2022
- Full Text
- View/download PDF
13. Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus 2019 guidelines. Short version
- Author
-
Juliette Abeillon-du Payrat, Georges Kaltenbach, Véronique Raverot, Lionel Groussin, Anne Cailleux, Pierre Wolff, Bernard Goichot, Olivier Lairez, Remy Leroy, Marc Klein, Philippe Caron, and Lavinia Vija Racaru
- Subjects
Aged, 80 and over ,Aging ,Pediatrics ,medicine.medical_specialty ,Consensus ,business.industry ,Endocrinology, Diabetes and Metabolism ,Thyroid ,MEDLINE ,General Medicine ,Thyroid Diseases ,Diagnostic Techniques, Endocrine ,Endocrinology ,medicine.anatomical_structure ,Geriatrics ,medicine ,Humans ,Endocrine system ,France ,Age of Onset ,Age of onset ,business ,Geriatric Assessment ,Societies, Medical ,Aged - Published
- 2020
- Full Text
- View/download PDF
14. Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus statement 2019. Long version
- Author
-
Lionel Groussin, Remy Leroy, Marc Klein, Philippe Caron, Georges Kaltenbach, Véronique Raverot, Olivier Lairez, Juliette Abeillon–Du Payrat, Anne Cailleux, Bernard Goichot, Pierre Wolff, and Lavinia Vija Racaru
- Subjects
Aging ,medicine.medical_specialty ,Consensus ,Health Services for the Aged ,Statement (logic) ,Health Status ,Endocrinology, Diabetes and Metabolism ,Thyroid Gland ,MEDLINE ,030209 endocrinology & metabolism ,Thyroid Function Tests ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,medicine ,Humans ,Endocrine system ,Geriatric Assessment ,Societies, Medical ,Aged ,Aged, 80 and over ,business.industry ,Thyroid ,Age Factors ,General Medicine ,Thyroid Diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Family medicine ,business ,Iodine - Abstract
Annales d'Endocrinologie - In Press. Accepted Manuscript Available online since lundi 4 mai 2020
- Published
- 2020
- Full Text
- View/download PDF
15. Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients
- Author
-
Serap Turan, Eileen M. Shore, Murat Bastepe, Olaf Hiort, Agnès Linglart, Francesca Elli, Roberto Bufo, Guiomar Perez de Nanclares, Michael A. Levine, Beatriz Lecumberri, M. Carola Zillikens, Rebeca Rodado, Vrinda Saraff, Ashley H. Shoemaker, Luisa De Sanctis, Guillemette Devernois, Gianpaolo De Filippo, Aurora Garcia Ramirez, Philip Murray, Susanne Thiele, Outi Mäkitie, Lars Rejnmark, Regina Matsunaga Martin, Manasori Minagawa, Timothee Choplin, Emily L. Germain-Lee, Giovanna Mantovani, Peter Kamenický, Harald Jüppner, Lionel Groussin, Nina Knight, Elvire Le Norcy, Anya Rothenbuhler, Neveen A. T. Hamdy, Robert J. Pignolo, David Monk, Thomas Eggermann, Caroline Silve, Arrate Pereda, Gabriel Á. Martos-Moreno, S Faisal Ahmed, Philip Woods, Patrick Hanna, Erasmus MC other, Internal Medicine, Mantovani, Giovanna, Bastepe, Murat, Monk, David, De Sanctis, Luisa, Thiele, Susanne, Ahmed, S. Faisal, Bufo, Roberto, Choplin, Timothee, De Filippo, Gianpaolo, Devernois, Guillemette, Eggermann, Thomas, Elli, Francesca M., Garcia Ramirez, Aurora, Germain-Lee, Emily L., Groussin, Lionel, Hamdy, Neveen A. T., Hanna, Patrick, Hiort, Olaf, Jueppner, Harald, Kamenicky, Peter, Knight, Nina, Le Norcy, Elvire, Lecumberri, Beatriz, Levine, Michael A., Maekitie, Outi, Martin, Regina, Martos-Moreno, Gabriel Angel, Minagawa, Manasori, Murray, Philip, Pereda, Arrate, Pignolo, Robert, Rejnmark, Lars, Rodado, Rebeca, Rothenbuhler, Anya, Saraff, Vrinda, Shoemaker, Ashley H., Shore, Eileen M., Silve, Caroline, Turan, Serap, Woods, Philip, Zillikens, M. Carola, Perez de Nanclares, Guiomar, Linglart, Agnes, HUS Children and Adolescents, Clinicum, Lastentautien yksikkö, Children's Hospital, University of Helsinki, and Helsinki University Hospital Area
- Subjects
Pediatrics ,Endocrinology, Diabetes and Metabolism ,Acrodysostosis ,Psychological intervention ,Type 2 diabetes ,Ossification ,Parathyroid hormone ,STIMULATORY G-PROTEIN ,0302 clinical medicine ,Endocrinology ,3123 Gynaecology and paediatrics ,Diagnosis ,SKELETAL RESPONSIVENESS ,Medicine ,Child ,Subclinical infection ,030219 obstetrics & reproductive medicine ,Brachydactyly ,Calcium and phosphate metabolism ,Management ,3. Good health ,IDENTIFIES PDE4D MUTATIONS ,Pseudohypoparathyroidism ,Practice Guidelines as Topic ,INCREASED PREVALENCE ,medicine.symptom ,Bone disorders ,Consensus ,Treatment ,Adult ,Transition to Adult Care ,medicine.medical_specialty ,Genetic counseling ,PARATHYROID-HORMONE ,PROGRESSIVE OSSEOUS HETEROPLASIA ,030209 endocrinology & metabolism ,HORMONE-RELEASING-HORMONE ,Short stature ,Article ,03 medical and health sciences ,PSEUDO-PSEUDOHYPOPARATHYROIDISM ,Hypothyroidism ,Humans ,Dwarfism, Pituitary ,ALBRIGHT HEREDITARY OSTEODYSTROPHY ,business.industry ,ENERGY-EXPENDITURE ,medicine.disease ,Diabetes Mellitus, Type 2 ,Pediatrics, Perinatology and Child Health ,business - Abstract
Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by physical findings that may include brachydactyly, a short stature, a stocky build, early-onset obesity, ectopic ossifications, and neurodevelopmental deficits, as well as hormonal resistance most prominently to parathyroid hormone (PTH). In addition to these alterations, patients may develop other hormonal resistances, leading to overt or subclinical hypothyroidism, hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable evidence for hormonal abnormalities, type 2 diabetes, and skeletal issues with potentially severe limitation of mobility. PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, radiological, and biochemical presentation, establishment of the molecular diagnosis is of critical importance for patients. It facilitates management, including prevention of complications, screening and treatment of endocrine deficits, supportive measures, and appropriate genetic counselling. Based on the first international consensus statement for these disorders, this article provides an updated and ready-to-use tool to help physicians and patients outlining relevant interventions and their timing. A life-long coordinated and multidisciplinary approach is recommended, starting as far as possible in early infancy and continuing throughout adulthood with an appropriate and timely transition from pediatric to adult care.
- Published
- 2020
- Full Text
- View/download PDF
16. Rapid control of severe ectopic Cushing’s syndrome by oral osilodrostat monotherapy
- Author
-
Florence Tenenbaum, Lionel Groussin, Jérôme Bertherat, Mathieu Jozwiak, Fidéline Bonnet, Anthony Corchia, and Laura Bessiene
- Subjects
medicine.medical_specialty ,Pediatrics ,S syndrome ,business.industry ,Endocrinology, Diabetes and Metabolism ,MEDLINE ,General Medicine ,Endocrinology ,Text mining ,Internal medicine ,medicine ,business ,Osilodrostat - Published
- 2021
- Full Text
- View/download PDF
17. Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma
- Author
-
Anne Jouinot, Juliane Lippert, Mathilde Sibony, Florian Violon, Lindsay Jeanpierre, Daniel De Murat, Roberta Armignacco, Amandine Septier, Karine Perlemoine, Franck Letourneur, Brigitte Izac, Bruno Ragazzon, Karen Leroy, Eric Pasmant, Marie-Odile North, Sébastien Gaujoux, Bertrand Dousset, Lionel Groussin, Rossella Libe, Benoit Terris, Martin Fassnacht, Cristina L Ronchi, Jérôme Bertherat, and Guillaume Assie
- Subjects
Paraffin Embedding ,Tissue Fixation ,Endocrinology, Diabetes and Metabolism ,Gene Expression Profiling ,General Medicine ,Prognosis ,Adrenal Cortex Neoplasms ,Endocrinology ,Paraffin ,Formaldehyde ,Adrenocortical Carcinoma ,Humans ,RNA ,Transcriptome ,Retrospective Studies - Abstract
Design Molecular classification is important for the diagnosis and prognosis of adrenocortical tumors (ACT). Transcriptome profiles separate adrenocortical adenomas ‘C2’ from carcinomas, and identify two groups of carcinomas ‘C1A’ and ‘C1B’, of poor and better prognosis respectively. However, many ACT cannot be profiled because of improper or absent freezing procedures, a mandatory requirement so far. The main aim was to determine transcriptome profiles on formalin-fixed paraffin-embedded (FFPE) samples, using the new 3’-end RNA-sequencing technology. A secondary aim was to demonstrate the ability of this technique to explore large FFPE archives, by focusing on the rare oncocytic ACT variants. Methods We included 131 ACT: a training cohort from Cochin hospital and an independent validation cohort from Wuerzburg hospital. The 3’ transcriptome was generated from FFPE samples using QuantSeq (Lexogen, Vienna, Austria) and NextSeq500 (Illumina, San Diego, CA, USA). Results In the training cohort, unsupervised clustering identified three groups: ‘C1A’ aggressive carcinomas (n = 28, 29%), ‘C1B’ more indolent carcinomas (n = 28, 29%), and ‘C2’ adenomas (n = 39, 41%). The prognostic value of FFPE transcriptome was confirmed in the validation cohort (5-year OS: 26% in ‘C1A’ (n = 26) and 100% in ‘C1B’ (n = 10), P = 0.003). FFPE transcriptome was an independent prognostic factor in a multivariable model including tumor stage and Ki-67 (OS HR: 7.5, P = 0.01). Oncocytic ACT (n = 19) did not form any specific cluster. Oncocytic carcinomas (n = 6) and oncocytic ACT of uncertain malignant potential (n = 4) were all in ‘C1B’. Conclusions The 3’ RNA-sequencing represents a convenient solution for determining ACT molecular class from FFPE samples. This technique should facilitate routine use and large retrospective studies.
- Published
- 2021
18. Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer
- Author
-
Béatrix Cochand-Priollet, Simon Garinet, Jeremie Zerbit, Jérôme Clerc, Olivier Huillard, Lionel Groussin, Laura Bessiene, Jennifer Arrondeau, and Audrey Lupo
- Subjects
MAPK/ERK pathway ,business.industry ,Radioiodine uptake ,Endocrinology, Diabetes and Metabolism ,Thyroid ,medicine.disease ,Endocrinology ,medicine.anatomical_structure ,Refractory ,Cancer research ,Medicine ,Radioactive iodine ,business ,Thyroid cancer - Abstract
Background. Metastatic thyroid cancers may dedifferentiate and become radioactive iodine refractory. The redifferentiating effect of pharmacological drugs was reported with inhibitors of the MAPK p...
- Published
- 2021
- Full Text
- View/download PDF
19. Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib
- Author
-
Martin Schlumberger, Olivier Huillard, Laure Cabanes, Anthony Dohan, Lionel Groussin, Caroline Bodet-Milin, Pascal Leprince, Sophie Leboulleux, Camille Buffet, Françoise Kraeber-Bodéré, Bernardo, Elizabeth, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de recherche clinique 16 – Tumeurs Thyroïdiennes [CHU Pitié-Salpêtrière] (GRC-TT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Intégrité du génome et cancers (IGC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
- Subjects
Oncology ,medicine.medical_specialty ,Medullary cavity ,business.industry ,Endocrinology, Diabetes and Metabolism ,Medullary thyroid cancers ,Thyroid ,Rearranged during transfection inhibitors ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Vandetanib ,Rearranged during transfection mutation ,medicine.anatomical_structure ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Internal medicine ,Long term survival ,medicine ,Cardiac metastasis ,Clinical Thyroidology / Case Report ,business ,medicine.drug - Abstract
Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a 68Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.
- Published
- 2021
- Full Text
- View/download PDF
20. An Ectopic Parathyroid Adenoma Mimicking a Carotid Body Paraganglioma
- Author
-
Rossella Libé, Anne-Ségolène Cottereau, Sébastien Gaujoux, Julien Calvani, Tatiana Lecot Connan, Myriam Wartski, and Lionel Groussin
- Subjects
medicine.medical_specialty ,ectopic parathyroid adenoma ,business.industry ,Endocrinology, Diabetes and Metabolism ,carotid body paraganglioma ,18F-FDOPA ,Carotid Body Paraganglioma ,18F-Choline PET/CT ,18f fdopa ,Image ,medicine ,Radiology ,business ,AcademicSubjects/MED00250 ,Ectopic parathyroid adenoma - Published
- 2020
- Full Text
- View/download PDF
21. Genomic classification of benign adrenocortical lesions
- Author
-
Bertrand Dousset, Simon Faillot, Anna Vaczlavik, Jean Guibourdenche, Lionel Groussin, Mathilde Sibony, Fideline Bonnet-Serrano, Stéphanie Espiard, Amandine Septier, Mario Neou, Ludivine Drougat, Marthe Rizk-Rabin, Bruno Ragazzon, Guillaume Assié, Simon Garinet, Thomas Foulonneau, Anne Jouinot, Windy Rondof, Rossella Libé, Karine Hecale-Perlemoine, Aurélien de Reyniès, Jérôme Bertherat, and Université de Paris, Institut Cochin, Institut National de la Santé et de la Recherche Médicale INSERM U1016, Centre National de la Recherche Scientifique CNRS UMR8104, F-75014 Paris.
- Subjects
0301 basic medicine ,Cortisol secretion ,Cancer Research ,Adenoma ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,Biology ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,medicine ,Humans ,Epigenetics ,Benign adrenal tumors ,Exome ,ComputingMilieux_MISCELLANEOUS ,Genomics ,Hyperplasia ,medicine.disease ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,030104 developmental biology ,Oncology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,030220 oncology & carcinogenesis ,DNA methylation ,Adrenocortical Adenoma ,Cancer research - Abstract
Benign adrenal tumors cover a spectrum of lesions with distinct morphology and steroid secretion. Current classification is empirical. Beyond a few driver mutations, pathophysiology is not well understood. Here, a pangenomic characterization of benign adrenocortical tumors is proposed, aiming at unbiased classification and new pathophysiological insights. Benign adrenocortical tumors (n = 146) were analyzed by transcriptome, methylome, miRNome, chromosomal alterations and mutational status, using expression arrays, methylation arrays, miRNA sequencing, SNP arrays, and exome or targeted next-generation sequencing respectively. Pathological and hormonal data were collected for all tumors. Pangenomic analysis identifies four distinct molecular categories: (1) tumors responsible for overt Cushing, gathering distinct tumor types, sharing a common cAMP/PKA pathway activation by distinct mechanisms; (2) adenomas with mild autonomous cortisol excess and non-functioning adenomas, associated with beta-catenin mutations; (3) primary macronodular hyperplasia with ARMC5 mutations, showing an ovarian expression signature; (4) aldosterone-producing adrenocortical adenomas, apart from other benign tumors. Epigenetic alterations and steroidogenesis seem associated, including CpG island hypomethylation in tumors with no or mild cortisol secretion, miRNA patterns defining specific molecular groups, and direct regulation of steroidogenic enzyme expression by methylation. Chromosomal alterations and somatic mutations are subclonal, found in less than 2/3 of cells. New pathophysiological insights, including distinct molecular signatures supporting the difference between mild autonomous cortisol excess and overt Cushing, ARMC5 implication into the adreno-gonadal differentiation faith, and the subclonal nature of driver alterations in benign tumors, will orient future research. This first genomic classification provides a large amount of data as a starting point.
- Published
- 2020
- Full Text
- View/download PDF
22. Frequency and incidence of Carney complex manifestations: A prospective multicenter study with a three-year follow-up
- Author
-
Catherine Cardot-Bauters, Francoise Archambeaud-Mouveroux, Muriel Houang, M.O. North, Gérald Raverot, Stéphanie Espiard, Anne Lienhardt, Hervé Lefebvre, Muriel Bottineau, Fidéline Bonnet, Denis Duboc, Olivier Chabre, Marie-Laure Nunes, Jérôme Bertherat, Antoine Feydy, Nicolas Dupin, Marie-Christine Vantyghem, Guillaume Assié, Sebastian Stroër, Françoise Brucker-Davis, L. Cabanes, Sophie Grabar, Antoine Tabarin, Lionel Groussin, and Laurence Guignat
- Subjects
Adult ,Male ,0301 basic medicine ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Cyclic AMP-Dependent Protein Kinase RIalpha Subunit ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Biochemistry ,Asymptomatic ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Prevalence ,medicine ,Humans ,Prospective Studies ,Carney Complex ,Child ,Multiple endocrine neoplasia ,Prospective cohort study ,Carney complex ,Aged ,Subclinical infection ,business.industry ,Incidence ,Incidence (epidemiology) ,Biochemistry (medical) ,Myxoma ,Retrospective cohort study ,Middle Aged ,medicine.disease ,030104 developmental biology ,Child, Preschool ,030220 oncology & carcinogenesis ,Cohort ,Female ,France ,medicine.symptom ,business ,Follow-Up Studies - Abstract
Introduction Carney Complex (CNC) is a rare multiple endocrine and nonendocrine neoplasia syndrome. Manifestations and genotype-phenotype correlations have been described by retrospective studies, but no prospective study evaluating the occurrence of the different manifestations has been available so far. Methods This multicenter national prospective study included patients with CNC, primary pigmented nodular adrenal disease (PPNAD), or a pathogenic PRKAR1A mutation; after a full initial workup, participants were followed for 3 years with annual standardized evaluation. Results The cohort included 70 patients (50 female/20 male, mean age 35.4 ± 16.7 years, 81% carrying PRKAR1A mutation). The initial investigations allowed identification of several manifestations. At the end of the 3-year follow-up, the newly diagnosed manifestations of the disease were subclinical acromegaly in 6 patients, bilateral testicular calcifications in 1 patient, and cardiac myxomas in 2 patients. Recurrences of cardiac myxomas were diagnosed in 4 patients during the 3-year follow-up study period. Asymptomatic abnormalities of the corticotroph and somatotroph axis that did not meet criteria of PPNAD and acromegaly were observed in 11.4% and 30% of the patients, respectively. Patients carrying the PRKAR1A c.709-7del6 mutation had a mild phenotype. Conclusion This study underlines the importance of a systematic follow-up of the CNC manifestations, especially a biannual screening for cardiac myxoma. By contrast, regular screening for the other manifestations after a first extensive workup could be spread out, leading to a lighter and more acceptable follow-up schedule for patients. These are important results for recommendations for long-term management of CNC patients.
- Published
- 2020
- Full Text
- View/download PDF
23. Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma
- Author
-
Mario Neou, Bertrand Dousset, Cristina L Ronchi, Sébastien Gaujoux, Juliane Lippert, Anne Jouinot, Bruno de La Villéon, Rossella Libé, Jérôme Bertherat, Lionel Groussin, Karine Perlemoine, Amandine Septier, Silke Appenzeller, Mathilde Sibony, Guillaume Assié, and Martin Fassnacht
- Subjects
0301 basic medicine ,Endocrinology, Diabetes and Metabolism ,intratumor heterogeneity ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Loss of heterozygosity ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Germline mutation ,CDKN2A ,Internal Medicine ,adrenocortical carcinoma ,chromosome alterations ,Medicine ,Adrenocortical carcinoma ,lcsh:RC648-665 ,business.industry ,Research ,Chromosome ,Methylation ,medicine.disease ,Primary tumor ,030104 developmental biology ,030220 oncology & carcinogenesis ,DNA methylation ,Cancer research ,somatic mutations ,methylation ,business - Abstract
Background: The prognosis of adrenocortical carcinoma (ACC) is heterogeneous. Genomic studies have identified ACC subgroups characterized by specific molecular alterations, including features measured at DNA level (somatic mutations, chromosome alterations, DNA methylation), which are closely associated with outcome. The aim of this study was to evaluate intratumor heterogeneity of prognostic molecular markers at the DNA level. Methods: Two different tissue samples (primary tumor, local recurrence or metastasis) were analyzed in 26 patients who underwent surgery for primary or recurrent ACC. DNA-related biomarkers with prognostic role were investigated in frozen and paraffin-embedded samples. Somatic mutations of p53/Rb and Wnt/β-catenin pathways were assessed using next-generation sequencing (n = 26), chromosome alteration profiles were determined using SNP arrays (n = 14) and methylation profiles were determined using four-gene bisulfite pyrosequencing (n = 12). Results: Somatic mutations for ZNRF3, TP53, CTNN1B and CDKN2A were found in 7, 6, 6 and 4 patients, respectively, with intratumor heterogeneity in 8/26 patients (31%). Chromosome alteration profiles were ‘Noisy’ (numerous and anarchic alterations) in 8/14 and ‘Chromosomal’ (extended patterns of loss of heterozygosity) in 5/14 of the study samples. For these profiles, no intratumor heterogeneity was observed. Methylation profiles were hypermethylated in 5/12 and non-hypermethylated in 7/12 of the study samples. Intratumor heterogeneity of methylation profiles was observed in 2/12 patients (17%). Conclusions: Intratumor heterogeneity impacts DNA-related molecular markers. While somatic mutation can differ, prognostic DNA methylation and chromosome alteration profile seem rather stable and might be more robust for the prognostic assessment.
- Published
- 2020
24. Redifferentiation of radioiodine-refractory thyroid cancers
- Author
-
Johanna Wassermann, Camille Buffet, Laurence Leenhardt, Fabio Hecht, Charlotte Lussey-Lepoutre, Lionel Groussin, Corinne Dupuy, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Intégrité du génome et cancers (IGC), Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), and Institut Gustave Roussy (IGR)
- Subjects
Epigenomics ,0301 basic medicine ,Sodium-iodide symporter ,Cancer Research ,Endocrinology, Diabetes and Metabolism ,Genetic enhancement ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Disease ,03 medical and health sciences ,Drug withdrawal ,0302 clinical medicine ,Endocrinology ,medicine ,Humans ,Thyroid Neoplasms ,Adverse effect ,ComputingMilieux_MISCELLANEOUS ,business.industry ,Thyroid ,Cell Differentiation ,Genetic Therapy ,medicine.disease ,3. Good health ,Clinical trial ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,business ,Tyrosine kinase ,Signal Transduction - Abstract
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to primary or acquired resistance or the necessity of drug withdrawal because of serious or moderate but chronic and deleterious adverse effects. Thus, the concept of redifferentiation strategy, which involves treating patients with one or more drugs capable of restoring radioiodine sensitivity for RAIR TC, has emerged. The area of redifferentiation strategy leads to the creation of new definitions of RAIR TC including persistent non radioiodine-avid patients and ‘true’ RAIR TC patients. The latter group presents a restored or increased radioiodine uptake in metastatic lesions but with no radiological response on conventional imaging, that is, progression of a metastatic disease, thus proving that they are ‘truly’ resistant to the radiation delivered by radioiodine. Unlike these patients, metastatic TC patients with restored radioiodine uptake offer the hope of prolonged remission or even cure of the disease as for radioiodine-avid metastatic TC. Here, we review the different redifferentiation strategies based on the underlying molecular mechanism leading to the sodium iodide symporter (NIS) and radioiodine uptake reinduction, that is, by modulating signaling pathways, NIS transcription, NIS trafficking to the plasma membrane, NIS post-transcriptional regulation, by gene therapy and other potential strategies. We discuss clinical trials and promising preclinical data of potential future targets.
- Published
- 2020
- Full Text
- View/download PDF
25. La diminution de l’activité de la CYP11B1 dans les tumeurs bilatérales de la corticosurrénale limite l’augmentation de l’amplitude de réponse du cortisol à l’ACTH : un mécanisme de compensation de l’augmentation du volume surrénalien ?
- Author
-
Anna Vaczlavik, Guillaume Assié, Fideline Bonnet-Serrano, L. Bessiène, Lionel Groussin, C. Laguillier-Morizot, Jean Guibourdenche, M.C. Menet, L. Guignat, and M. Barat
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Objectif La regulation de la steroidogenese dans les tumeurs bilaterales de la corticosurrenale est peu decrite dans la litterature. Notre objectif etait d’etudier l’amplitude de reponse a l’ACTH des glucocorticoides et de leurs precurseurs dans les tumeurs surrenaliennes bilaterales. Materiels et methodes Trente-sept patients porteurs de tumeurs surrenaliennes bilaterales (BL), 38 patients atteints de tumeurs unilaterales (UL), et 37 controles (CT), ayant beneficie d’un test au synacthene entre decembre 2018 et mars 2021, ont ete inclus. Quatre steroides consecutifs sur l’axe des glucocorticoides (progesterone > 17OHprogesterone > 11-desoxycortisol > cortisol) ont ete doses en LC-MS/MS sur le T0 et le T60 du test au synacthene. Le volume surrenalien global a ete quantifie dans les BL et les UL a partir des scanners surrenaliens selon une methode de segmentation manuelle. Resultats L’amplitude de reponse des 4 steroides etudies, mesuree par le ratio T60/T0, etait superieure dans les BL par rapport aux CT et aux UL, l’amplitude de reponse des precurseurs (17OHP, 11-desoxycortisol) etant superieure a celle du cortisol. La difference entre les BL et les UL disparaissait apres normalisation de l’amplitude par le volume surrenalien. L’activite enzymatique de la CYP11B1, mesuree par le ratio cortisol/11-desoxycortisol au T60 etait diminuee dans les BL par rapport aux CT (78,3 versus 186,8, P Discussion L’activite de la CYP11B1, etape limitante de la voie de biosynthese du cortisol, est diminuee dans les tumeurs BL pour compenser l’augmentation de la masse surrenalienne.
- Published
- 2021
- Full Text
- View/download PDF
26. Épi-Hypo : état des lieux du suivi des recommandations pour la prise en charge de l’hypoparathyroïdie chronique en France
- Author
-
Marie-Christine Vantyghem, Peter Kamenicky, G. Maruani, C. Sido, A. Lienhardt-Roussie, Pascal Houillier, E. Miraillié, Jean-Philippe Bertocchio, Agnès Linglart, Caroline Silve, A. Vilfaillot, Lionel Groussin, N. Grosset, A. Tabarin, François Pattou, Riyad N.H. Seervai, and Fabrice Larceneux
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Introduction Peu d’informations existent sur la prise en charge de l’hypoparathyroidie chronique en vie reelle. Notre objectif est d’etudier l’adequation des pratiques (suivi et objectifs du traitement) avec les recommandations internationales. Methodes Nous utilisons les donnees d’un sous-groupe de la e-cohorte francaise Epi-Hypo (118 medecins et 107 patients, 09/2016-12/2019) et celles d’une enquete en ligne (110 ePatients, 11/2019). Les participants devaient etre i) medecin prenant en charge des patients avec hypoparathyroidie chronique ou ii) patient participant a la cohorte Epi-Hypo ou iii) patient de l’association Hypoparathyroidisme France (ePatients). Resultats Endocrinologues et nephrologues representent 89 % des medecins mais d’autres specialites sont aussi impliquees. L’association vitamine D active/sels de calcium est donnee a 58-59 % des patients. La majorite (85-87 %) des medecins suit la calcemie au moins 2 fois/an a l’etat stable. Les recommandations internationales conseillent de controler les symptomes, les valeurs de calcemie, de phosphatemie et de calciurie : un controle simultane de tous ces facteurs est rapporte par 32 % des ePatients et 26 % des medecins. La majorite (80 %) des ePatients rapportent que leurs symptomes sont insuffisamment controles par le traitement en cours alors que leur suivi est similaire a ceux dont les symptomes sont controles. Leur traitement est similaire en dehors des sels de magnesium qu’ils recoivent plus frequemment que les autres. Discussion De nombreuses specialites sont impliquees dans la prise en charge des patients avec hypoparathyroidie chronique en France : les recommandations devraient les cibler car l’adherence est encore faible. De nouveaux traitements sont necessaires pour mieux controler les symptomes.
- Published
- 2021
- Full Text
- View/download PDF
27. Diagnostic d’insulinome : réévaluation des valeurs seuils de glycémie, d’insuline et de peptide C sur une cohorte rétrospective monocentrique de 132 épreuves de jeûne de 72 heures
- Author
-
Jean Guibourdenche, Benoit Terris, Fideline Bonnet-Serrano, C. Devingenteuil, H. Mosnier-Pudar, Anna Vaczlavik, C. Laguillier-Morizot, L. Bessiène, Lionel Groussin, Guillaume Assié, and Jérôme Bertherat
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Objectif L’epreuve de jeune reste la methode de reference pour confirmer le diagnostic d’insulinome sur la survenue d’une hypoglycemie associee a des taux d’insuline et de peptide C eleves inadaptes. Neanmoins, les valeurs seuils retenues pour le diagnostic ne sont pas consensuelles et la determination de l’insulinemie peut etre mise en defaut en cas de prelevement hemolyse. Materiels et methodes Nous avons analyse de maniere retrospective les resultats des epreuves de jeune des 132 patients hospitalises dans le service d’Endocrinologie de l’Hopital Cochin entre fevrier 2012 et decembre 2020. Les resultats sont exprimes en mediane (minimum-maximum). Resultats Le diagnostic d’hyperinsulinisme endogene (HE) a ete pose chez 21 des 132 patients etudies: 20 cas d’insulinomes et un cas d’HE congenital. Le nadir de glycemie etait plus bas dans le groupe HE 1,8 (1,28–2,3) mmol/L versus 2,93 (1,47–4,85) mmol/L (p 0,2 nmol/L permettaient de poser le diagnostic d’HE avec une sensibilite de 100 % et une specificite de 98 %. Discussion Un seuil de glycemie ≤ 2,3 mmol/L et de C-peptide > 0,2 nmol/L sans critere sur l’insulinemie donnent de meilleures performances diagnostiques que les recommandations actuelles pour le diagnostic d’HE.
- Published
- 2021
- Full Text
- View/download PDF
28. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
- Author
-
Jérôme Clerc, Nora Kramkimel, C. Lheure, Gaëlle Lethielleux, Carole Ratour, Lionel Groussin, Jérôme Bertherat, and Anne-Cécile Paepegaey
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Levothyroxine ,030209 endocrinology & metabolism ,Pembrolizumab ,Case Reports ,Gastroenterology ,Thyroiditis ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Adrenal insufficiency ,Adrenal ,Adverse effect ,business.industry ,Melanoma ,Adrenal crisis ,medicine.disease ,030220 oncology & carcinogenesis ,Immunology ,thyroiditis ,polyendocrinopathy ,pembrolizumab ,medicine.symptom ,Hyponatremia ,business ,adrenal insufficiency ,checkpoint inhibitors ,medicine.drug - Abstract
Introduction: Checkpoint inhibitors have significantly improved the prognosis of patients with advanced melanoma. These cancer immunotherapy drugs have specific endocrine autoimmune toxicity. We describe a case of an adrenal insufficiency secondary to pembrolizumab, an anti-programmed cell death-1 monoclonal antibody. Moreover, this case of polyendocrinopathy resulting from a pembrolizumab as the adrenal insufficiency occurred after a thyroiditis. Participant: A 55-year-old female was started on pembrolizumab immunotherapy for a metastatic choroidal melanoma. Five months after initiation, she suffered from thyrotoxicosis. A thyroiditis was diagnosed by iodine-123 thyroid scintigraphy and ultrasonography. Pembrolizumab therapy was maintained. Two weeks later, without any other treatment given, she patient developed hypothyroidism and levothyroxine substitution was started. Pembrolizumab proved to be ineffective and was stopped 9 months after initiation. One month following its discontinuation, the patient was hospitalized in the intensive care unit. Severe hyponatremia (115 mmol/L) associated with hyperkalemia (5.7 mmol/L) led to the early recognition and treatment of an acute adrenal insufficiency. Positive results for adrenal cortex and 21-hydroxylase antibodies were in favor of autoimmune toxicity. Conclusion: This case highlights the diversity of potential endocrine toxicity of checkpoint inhibitors. Because acute adrenal crisis may be associated with substantial morbidity and mortality, physicians must be aware of these rare adverse events to allow an early diagnosis., We present a case of adrenal insufficiency secondary to pembrolizumab and of polyendocrinopathy secondary to pembrolizumab.
- Published
- 2017
29. Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B–Secreting Adrenocortical Carcinoma
- Author
-
Najiba Lahlou, Stéphanie Espiard, Estelle Louiset, Bertrand Dousset, Marie Bienvenu, Mathilde Sibony, Lionel Groussin, Jérôme Bertherat, Rossella Libé, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biologie hormonale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Saint-Vincent de Paul, Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Différenciation et communication neuronale et neuroendocrine (DC2N), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroendocrinologie cellulaire et moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), [Institut Cochin] Département Endocrinologie, métabolisme, diabète (EMD) (EMD), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gynécologie et d'endocrinologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Saint-Vincent de Paul, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,endocrine system ,Endocrinology, Diabetes and Metabolism ,education ,030209 endocrinology & metabolism ,Gonadotropin-releasing hormone ,Case Reports ,inhibin B ,03 medical and health sciences ,Follicle-stimulating hormone ,Cushing syndrome ,0302 clinical medicine ,Internal medicine ,[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB] ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,medicine ,adrenocortical carcinoma ,Adrenocortical carcinoma ,Mitotane ,Adrenal ,business.industry ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,3. Good health ,Endocrinology ,030220 oncology & carcinogenesis ,tumor marker ,business ,Luteinizing hormone ,Immunostaining ,hormones, hormone substitutes, and hormone antagonists ,Hormone ,medicine.drug - Abstract
Context: Adrenocortical carcinomas (ACCs) are revealed in 60% of cases by steroid hypersecretion. Alternatively, it is uncommon to observe a paraneoplastic syndrome due to a peptide oversecretion. Case Description: We describe a 60-year-old man with a right adrenal mass. Hormonal evaluation showed an ACTH-independent Cushing syndrome. Surprisingly, follicle-stimulating hormone (FSH) levels were suppressed and blunted during gonadotropin-releasing hormone stimulation, despite normal luteinizing hormone levels. Levels of inhibin B, which negatively regulates the pituitary FSH, were very high. Given the atypical hormonal findings, an adrenal mass biopsy was performed, which allowed the diagnosis of an adrenocortical tumor (positive for steroidogenic factor-1 immunostaining). Moreover, an intense α-inhibin subunit immunostaining was observed. Because of the presence of metastases, the patient received mitotane and chemotherapy (etoposide and cisplatin). After 2 cycles, the inhibin B dropped. After 5 cycles, tumor size was reduced by 15%. Inhibin B levels remained low, and basal and gonadotropin-releasing hormone–stimulated FSH levels normalized. The patient underwent tumor resection, and pathology confirmed the ACC diagnosis (Weiss score of 9). The intensity of the α-inhibin subunit immunostaining was significantly decreased. Conclusions: We report the case of an inhibin B–secreting ACC in which the response to chemotherapy and mitotane was associated with a normalization of inhibin B secretion, allowing the reversal of the blunted FSH secretion. Inhibin B should be measured in case of suppressed FSH levels despite normal luteinizing hormone levels and may be considered a tumoral marker in some ACCs, even during treatment follow-up., Precis: We studied an adrenal mass with suppressed FSH levels, blunted after GnRH stimulation, and found an inhibin B–secreting adrenocortical carcinoma, in which inhibin B was normalized after chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
30. Visualization of Macroprolactinoma by 18F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1
- Author
-
Anne-Cécile Paepegaey, Mathieu Gauthé, Anne-Ségolène Cottereau, Sébastien Gaujoux, and Lionel Groussin
- Subjects
PET-CT ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Pituitary and Neuroendocrinology ,medicine.disease ,030218 nuclear medicine & medical imaging ,Visualization ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,030220 oncology & carcinogenesis ,Image ,Medicine ,Radiology ,Macroprolactinoma ,business ,Multiple endocrine neoplasia ,18F-fluorocholine - Published
- 2018
- Full Text
- View/download PDF
31. 18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease
- Author
-
Jean-François Jazeron, Rossella Libé, Estelle Louiset, Lionel Groussin, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de La Rochelle (CHR), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Institut National de la Santé et de la Recherche Médicale (INSERM), Différenciation et communication neuronale et neuroendocrine (DC2N), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Adrenal Cortex Diseases ,Male ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Disease ,MESH: Adrenal Cortex Neoplasms ,030218 nuclear medicine & medical imaging ,18f fdg pet ,03 medical and health sciences ,MESH: Adrenocortical Carcinoma ,0302 clinical medicine ,Endocrinology ,X ray computed ,Fluorodeoxyglucose F18 ,MESH: Fluorodeoxyglucose F18 ,Diabetes mellitus ,[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB] ,medicine ,Adrenocortical Carcinoma ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Adrenocortical carcinoma ,Humans ,ComputingMilieux_MISCELLANEOUS ,MESH: Adrenalectomy ,MESH: Humans ,MESH: Middle Aged ,medicine.diagnostic_test ,business.industry ,Adrenalectomy ,MESH: Adrenal Cortex Diseases ,Middle Aged ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,Adrenal Cortex Neoplasms ,MESH: Male ,MESH: Positron-Emission Tomography ,3. Good health ,Positron emission tomography ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Tomography ,Radiopharmaceuticals ,Nuclear medicine ,business ,Tomography, X-Ray Computed ,MESH: Tomography, X-Ray Computed ,MESH: Radiopharmaceuticals - Abstract
International audience
- Published
- 2019
- Full Text
- View/download PDF
32. Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
- Author
-
Jérôme Clerc, Olivier Huillard, François Goldwasser, Lionel Groussin, and Florence Tenenbaum
- Subjects
endocrine system diseases ,business.industry ,Radioiodine uptake ,Endocrinology, Diabetes and Metabolism ,Dabrafenib ,Metastatic papillary thyroid carcinoma ,medicine.disease ,digestive system diseases ,Papillary thyroid cancer ,BRAF V600E ,enzymes and coenzymes (carbohydrates) ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Cancer research ,Medicine ,030212 general & internal medicine ,skin and connective tissue diseases ,business ,Vemurafenib ,neoplasms ,Thyroid cancer ,Therapeutic strategy ,medicine.drug - Abstract
This image illustrates a multimodal therapeutic strategy for an iodine-refractory BRAF-mutated metastatic papillary thyroid carcinoma with reversed radioiodine resistance using BRAF inhibitors.
- Published
- 2017
- Full Text
- View/download PDF
33. Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma
- Author
-
Pascaline Boudou-Rouquette, Léopoldine Bricaire, Mathilde Briere, Jérôme Bertherat, Myriam Edjlali, Marguerite d’Ussel, Chiara Villa, Frédérique Larousserie, and Lionel Groussin
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Epithelioid Angiosarcoma ,Pituitary and Neuroendocrinology ,digestive system diseases ,Lesion ,hemic and lymphatic diseases ,mental disorders ,medicine ,Etiology ,Images ,medicine.symptom ,business ,neoplasms - Abstract
Precis: We report the unusual etiology of a sellar aggressive mass, an epithelioid angiosarcoma, the diagnosis of which was made from positive epithelial and vascular markers.
- Published
- 2017
34. NEM 1 : prise en charge thérapeutique
- Author
-
Lionel Groussin and Peter Kamenicky
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
La neoplasie endocrine multiple de type 1 (NEM1) est une maladie genetique rare, de transmission autosomique dominante, due a une mutation heterozygote inactivatrice du gene codant pour la menine. La NEM1 a une penetrance quasiment complete, avec une expressivite variable. L’hyperparathyroidie primaire est la manifestation la plus frequente, presente chez la plupart des patients a l’âge de 50 ans. Les tumeurs neuroendocrines pancreatiques et les adenomes hypophysaires sont les autres atteintes les plus frequentes a depister au cours du suivi. Les tumeurs endocrines thymiques sont plus rares, mais posent des questions specifiques de depistage et de traitement. Au cours des dernieres annees la connaissance de cette maladie a progresse, notamment grâce aux donnees de differents registres. Nous allons aborder les dernieres actualites concernant la prise en charge des principales manifestations, en insistant sur les nouvelles approches diagnostiques en imagerie fonctionnelle et les nouvelles pistes de traitement preventif ou curatif.
- Published
- 2020
- Full Text
- View/download PDF
35. Diagnosis and management of pseudohypoparathyroidism and related disorders:first international Consensus Statement
- Author
-
Susanne Thiele, Eileen M. Shore, Luisa De Sanctis, Thomas Eggermann, Serap Turan, Murat Bastepe, Gabriel Á. Martos-Moreno, Aurora Garcia Ramirez, Vrinda Saraff, Nina Knight, Caroline Silve, Outi Mäkitie, Agnès Linglart, Marie Laure Kottler, Emily L. Germain-Lee, Rebecca Rodado, Philip Murray, Peter Kamenický, Lars Rejnmark, Masanori Minagawa, Anya Rothenbuhler, Kathleen Freson, Timothee Choplin, Alessia Usardi, Francesca Elli, Regina Matsunaga Martin, M. Carola Zillikens, Guillemette Devernois, Harald Jüppner, David Monk, Arrate Pereda, Neveen A. T. Hamdy, Gianpaolo de Filippo, Lionel Groussin, Elvire Le Norcy, Robert J. Pignolo, Ashley H. Shoemaker, Giovanna Mantovani, Olaf Hiort, Roberto Bufo, Guiomar Perez de Nanclares, Michael A. Levine, Beatriz Lecumberri, Philip Woods, Patrick Hanna, S Faisal Ahmed, Mantovani, Giovanna, Bastepe, Murat, Monk, David, de Sanctis, Luisa, Thiele, Susanne, Usardi, Alessia, Ahmed, S. Faisal, Bufo, Roberto, Choplin, Timothee, De Filippo, Gianpaolo, Devernois, Guillemette, Eggermann, Thomas, Elli, Francesca M., Freson, Kathleen, Garcia Ramirez, Aurora, Germain-Lee, Emily L., Groussin, Lionel, Hamdy, Neveen, Hanna, Patrick, Hiort, Olaf, Juppner, Harald, Kamenicky, Peter, Knight, Nina, Kottler, Marie-Laure, Le Norcy, Elvire, Lecumberri, Beatriz, Levine, Michael A., Makitie, Outi, Martin, Regina, Angel Martos-Moreno, Gabriel, Minagawa, Masanori, Murray, Philip, Pereda, Arrate, Pignolo, Robert, Rejnmark, Lars, Rodado, Rebecca, Rothenbuhler, Anya, Saraff, Vrinda, Shoemaker, Ashley H., Shore, Eileen M., Silve, Caroline, Turan, Serap, Woods, Philip, Zillikens, M. Carola, Perez de Nanclares, Guiomar, Linglart, Agnes, Clinicum, Lastentautien yksikkö, Children's Hospital, HUS Children and Adolescents, Internal Medicine, UAM. Departamento de Medicina, UAM. Departamento de Pediatría, Instituto de Investigación del Hospital de La Princesa (IP), Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ), Università degli Studi di Milano = University of Milan (UNIMI), Harvard Medical School [Boston] (HMS), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Università degli studi di Torino = University of Turin (UNITO), Lübeck University of Applied Sciences, Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Glasgow, Italian Progressive Osseous Heteroplasia Association (IPOHA), Service d'endocrinologie pédiatrique [CHU Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Connecticut Children's Medical Center, University of Connecticut (UCONN), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Université Paris Descartes - Paris 5 (UPD5), Leiden University Medical Center (LUMC), Universiteit Leiden, Thérapie génique, Génomique et Epigénomique (U 1169), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Endocrine Unit, Massachusetts General Hospital [Boston], Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie, génétique et thérapies ostéoarticulaires et respiratoires (BIOTARGEN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Service de Génétique [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Pathologies, Imagerie et Biothérapies oro-faciales (EA 2496), Hospital Universitario La Paz, Department of Statistics [West Lafayette], Purdue University [West Lafayette], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universidade de São Paulo = University of São Paulo (USP), Chiba University Hospital, Manchester University NHS Foundation Trust (MFT), Bioaraba Health Research Institute, Mayo Clinic [Rochester], Aarhus University Hospital, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Birmingham Children’s Hospital, Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], University of Pennsylvania, Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Marmara University [Kadıköy - İstanbul], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Immunologie et génétique du diabète de type 1, génétique multifactorielle en endocrinologie pédiatrique (U986), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Departments of Medicine and Pediatrics, Department of Pediatrics, University of Turin, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Collège de France (CdF)-PSL Research University (PSL), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Center for Molecular and Vascular Biology, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universität zu Lübeck [Lübeck] - University of Lübeck [Lübeck], Endocrine Unit, Department of Medicine, and Pediatric Neprology Unit, MassGeneral Hospital for Children, Servicio de Endocrinología, Hospital Universitario La Paz, Hospital for Children and Adolescents, Helsinki University Central Hospital, Netherlands Genomics Initiative, Netherlands Consortium for Healthy Aging [Leiden, Netherlands] (NCHA), Laboratorio de Genética Molecular, Unidad de Investigación, Hospital de Txagorritxu, University of Milan, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR93-Université Paris-Sud - Paris 11 (UP11), University of Helsinki, University of São Paulo (USP), University of Pennsylvania [Philadelphia], Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), and Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,0301 basic medicine ,Pediatrics ,Delayed Diagnosis ,Endocrinology, Diabetes and Metabolism ,Endocrinology ,Statement (logic) ,Drug Resistance ,Parathyroid hormone ,MESH: Risk Assessment ,Pseudohypoparathyroidism/diagnosis ,STIMULATORY G-PROTEIN ,Neonatal Screening/organization & administration ,0302 clinical medicine ,MESH: Practice Guidelines as Topic ,Program Development ,BRACHYDACTYLY TYPE-E ,PARATHYROID-HORMONE RESISTANCE ,Disorders ,IMPRINTING CONTROL ELEMENT ,MESH: Infant, Newborn ,MESH: Pseudohypoparathyroidism ,MESH: Genetic Predisposition to Disease ,Prognosis ,3. Good health ,Diabetes and Metabolism ,MESH: Parathyroid Hormone ,IDENTIFIES PDE4D MUTATIONS ,Parathyroid Hormone ,NUCLEOTIDE REGULATORY PROTEIN ,Consensus statement ,Pseudohypoparathyroidism ,Practice Guidelines as Topic ,MESH: Drug Resistance ,Female ,medicine.symptom ,Parathyroid Hormone/therapeutic use ,medicine.medical_specialty ,Consensus ,Delayed Diagnosis/adverse effects ,Medicina ,030209 endocrinology & metabolism ,PROGRESSIVE OSSEOUS HETEROPLASIA ,Parathyroid Hormone Resistance ,Risk Assessment ,Short stature ,PATERNAL UNIPARENTAL DISOMY ,Article ,MESH: Prognosis ,Growth hormone deficiency ,GNAS INACTIVATING MUTATIONS ,03 medical and health sciences ,Neonatal Screening ,BECKWITH-WIEDEMANN SYNDROME ,MESH: Program Development ,medicine ,Humans ,Genetic Predisposition to Disease ,MESH: Consensus ,MESH: Neonatal Screening ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,GS-ALPHA-GENE ,MESH: Humans ,ALBRIGHT HEREDITARY OSTEODYSTROPHY ,business.industry ,Brachydactyly ,Infant, Newborn ,Type 2 Diabetes Mellitus ,medicine.disease ,MESH: Male ,MESH: Delayed Diagnosis ,030104 developmental biology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Diagnosis and management ,DEPENDENT PROBE AMPLIFICATION ,Family medicine ,3121 General medicine, internal medicine and other clinical medicine ,business ,MESH: Female ,Neurocognitive - Abstract
This Consensus Statement covers recommendations for the diagnosis and management of patients with pseudohypoparathyroidism (PHP) and related disorders, which comprise metabolic disorders characterized by physical findings that variably include short bones, short stature, a stocky build, early-onset obesity and ectopic ossifications, as well as endocrine defects that often include resistance to parathyroid hormone (PTH) and TSH. The presentation and severity of PHP and its related disorders vary between affected individuals with considerable clinical and molecular overlap between the different types. A specific diagnosis is often delayed owing to lack of recognition of the syndrome and associated features. The participants in this Consensus Statement agreed that the diagnosis of PHP should be based on major criteria, including resistance to PTH, ectopic ossifications, brachydactyly and early-onset obesity. The clinical and laboratory diagnosis should be confirmed by a molecular genetic analysis. Patients should be screened at diagnosis and during follow-up for specific features, such as PTH resistance, TSH resistance, growth hormone deficiency, hypogonadism, skeletal deformities, oral health, weight gain, glucose intolerance or type 2 diabetes mellitus, and hypertension, as well as subcutaneous and/or deeper ectopic ossifications and neurocognitive impairment. Overall, a coordinated and multidisciplinary approach from infancy through adulthood, including a transition programme, should help us to improve the care of patients affected by these disorders, This Consensus Statement and the series of consensus meetings were supported by funds from the European Cooperation in Science and Technology (COST) action BM1208 on imprinting disorders (www.imprinting- disorders.eu), the European Society for Paediatric Endocrinology (ESPE) and the European Society for Endocrinology (ESE). Travel costs and housing of the representatives of the Asian Pacific Paediatric Endocrine Society (APPES) and of the Pediatric Endocrine Society (PES) were supported by their societies. The authors received no funding from pharmaceutical companies
- Published
- 2018
- Full Text
- View/download PDF
36. Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma
- Author
-
Mario Neou, Olivier Soubrane, Guillaume Assié, Lucie Orhant, Juliana Pipoli da Fonseca, Franck Letourneur, Jérôme Bertherat, Anne Jouinot, Eric Pasmant, Lionel Groussin, Rossella Libé, Bertrand Dousset, Juliette Nectoux, Karine Perlemoine, Léopoldine Bricaire, Simon Garinet, Mathilde Sibony, Service de parasitologie - mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Genetique et Biotherapies des Maladies Degeneratives et Proliferatives du Systeme Nerveux (Inserm U745), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement (IFR71), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biochimie et biologie moléculaire, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de chirurgie hepato-pancreato-biliaire, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Cochin (UMR_S567 / UMR 8104), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,Sequence analysis ,Endocrinology, Diabetes and Metabolism ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Circulating Tumor DNA ,03 medical and health sciences ,chemistry.chemical_compound ,Endocrinology ,X ray computed ,Adrenocortical Carcinoma ,Medicine ,Adrenocortical carcinoma ,Humans ,ComputingMilieux_MISCELLANEOUS ,Aged ,Aged, 80 and over ,business.industry ,Sequence Analysis, DNA ,Middle Aged ,medicine.disease ,Adrenal Cortex Neoplasms ,030104 developmental biology ,Oncology ,chemistry ,Circulating tumor DNA ,Cancer research ,Female ,business ,Tomography, X-Ray Computed ,DNA - Abstract
International audience
- Published
- 2018
- Full Text
- View/download PDF
37. The Great Imitator in Endocrinology: A Painful Hypophysitis Mimicking a Pituitary Tumor
- Author
-
Clélia Van Haecke, Nicolas Dupin, Grace Jrad, Sara Laurent-Roussel, Michèle Bernier, Lionel Groussin, Jérôme Bertherat, Stephan Gaillard, and Léopoldine Bricaire
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pituitary gland ,Pathology ,Hypophysitis ,Pituitary Diseases ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Clinical Biochemistry ,The great imitator ,Pituitary neoplasm ,Biochemistry ,Diagnosis, Differential ,Endocrinology ,Neurosyphilis ,Internal medicine ,Headache Disorders, Secondary ,medicine ,Humans ,Pituitary Neoplasms ,Transsphenoidal surgery ,business.industry ,Biochemistry (medical) ,Pituitary tumors ,medicine.disease ,medicine.anatomical_structure ,Encephalitis ,Syphilis ,Headaches ,medicine.symptom ,business - Abstract
The incidence of syphilis has been increasing in recent decades in Western countries. Pituitary involvement is very unusual in syphilis. This infectious disease is not often considered in the workup of a patient with hypophysitis.We report the case of a 28-year-old man who was admitted for headaches worsening over 1 month that became resistant to paracetamol. A magnetic resonance imaging scan revealed a heterogeneous pituitary mass suggesting a pituitary tumor. Hormonal investigations showed partial corticotropic and thyrotropic deficiencies. Headaches required high doses of morphine. Transsphenoidal surgery was performed, and histological examination revealed an aspect of hypophysitis. One month later, clinical reexamination showed skin and tongue lesions very suggestive of a syphilis infection, which was serologically confirmed. Immunohistochemistry on paraffin sections of the resected pituitary revealed an abundant presence of Treponema pallidum, confirming the diagnosis of a syphilitic hypophysitis. Intravenous therapy by benzylpenicillin for 14 days was rapidly efficient. Headaches stopped within a few days, and the skin and tongue lesions disappeared during the following month. Thyrotropic deficiency resolved in 2 weeks, but partial corticotropic deficiency persisted at 3 months.This is the first case of a pituitary involvement in acquired syphilis, pathologically proven, in a non-HIV-infected patient. In a context of the resurgence of syphilis, this diagnosis should be considered in the case of a pituitary lesion with unusually intense headaches.
- Published
- 2015
- Full Text
- View/download PDF
38. Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study
- Author
-
Catherine Cardot-Bauters, Philippe Caron, Nicolas Carrere, Jean Louis Peix, Philippe Chanson, Eric Mirallié, P. Lecomte, Antoine Tabarin, Philippe Bouchard, Pierre Goudet, I. Guilhem, Vanina Bongard, Mireille Bertholon-Gregoire, Lionel Groussin, Françoise Borson-Chazot, N. Bouscaren, Eric Baudin, Nathalie Lévy-Bohbot, Maëlle Lebras, Diane Goéré, François Pattou, Delphine Vezzosi, Patricia Niccoli, and Bruno Carnaille
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Recurrent hypoglycemia ,Enucleation ,Context (language use) ,Hypoglycemia ,Pancreaticoduodenectomy ,Young Adult ,Pancreatectomy ,Endocrinology ,Internal medicine ,Multiple Endocrine Neoplasia Type 1 ,medicine ,Humans ,Insulinoma ,Retrospective Studies ,business.industry ,Hazard ratio ,Retrospective cohort study ,General Medicine ,medicine.disease ,Female ,business - Abstract
ObjectiveManagement of insulinomas in the context of MEN1 remains poorly studied. The aim of this study was to evaluate long-term results of various surgical approaches in a large cohort of insulinoma–MEN1 patients.Design and methodsConsecutive insulinoma–MEN1 patients operated on for a nonmetastatic insulinoma between 1957 and 2010 were retrospectively selected from the MEN1 database of the French Endocrine Tumor Group. The type of surgery was categorized as distal pancreatectomy (DP), total pancreatectomy/cephalic duodenopancreatectomy (TP/CDP), or enucleation (E). Primary endpoint was time until recurrence of hypoglycemia after initial surgery. Secondary endpoints were post-operative complications.ResultsThe study included 73 patients (median age=28 years). Surgical procedures were DP (n=46), TP/CDP (n=9), or E (n=18). After a median post-operative follow-up of 9.0 years (inter-quartile range (IQR): 2.5–16.5 years), 60/73 patients (82.2%) remained hypoglycemia free. E and TP/CDP were associated with a higher risk of recurrent hypoglycemia episodes (unadjusted hazard ratio: 6.18 ((95% CI: 1.54–24.8);P=0.010) for E vs DP and 9.51 ((95% CI: 1.85–48.8);P=0.007) for TP/CDP vs DP. After adjustment for International Union against Cancer pTNM classification, enucleation remained significantly associated with a higher probability of recurrence. Long-term complications had occurred in 20 (43.5%) patients with DP, five (55.6%) with TP/CDP, but in none of the patients who have undergone E (P=0.002).ConclusionIn the French Endocrine database, DP is associated with a lower risk for recurrent hypoglycemia episodes. Due to lower morbidity, E alone might be considered as an alternative.
- Published
- 2015
- Full Text
- View/download PDF
39. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery
- Author
-
Abir Al Ghuzlan, Marie-Elisabeth Toubert, Sophie Leboulleux, Pierre-Jean Lamy, Slimane Zerdoud, Anne-Laure Giraudet, Isabelle Keller, Renaud Garrel, Elif Hindié, Lionel Groussin, Stéphane Bardet, Eric Mirallié, David Taïeb, Frederic Sebag, Laurence Leenhardt, Jérôme Clerc, Claire Bournaud, Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de médecine nucléaire [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Clinique Beau Soleil [Montpellier], Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), [Institut Cochin] Département Endocrinologie, métabolisme, diabète (EMD) (EMD), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
medicine.medical_specialty ,Pathology ,Consensus ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,MEDLINE ,030209 endocrinology & metabolism ,Biology ,Iodine Radioisotopes ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Serum biomarkers ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Thyroid Neoplasms ,Radionuclide Imaging ,Thyroid cancer ,ComputingMilieux_MISCELLANEOUS ,business.industry ,General Medicine ,medicine.disease ,Molecular Imaging ,3. Good health ,Endocrine surgery ,030220 oncology & carcinogenesis ,Thyroidectomy ,Head and neck surgery ,Neck Dissection ,France ,Radioactive iodine therapy ,Nuclear Medicine ,Molecular imaging ,Nuclear medicine ,business - Abstract
International audience
- Published
- 2017
- Full Text
- View/download PDF
40. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation
- Author
-
Marie Bienvenu-Perrard, Anne-Cécile Paepegaey, Najiba Lahlou, Lionel Groussin, Estelle Louiset, Léopoldine Bricaire, Béatrix Cochand-Priollet, Marco Alifano, Nelly Burnichon, Pierre-Olivier Sarfati, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Différenciation et communication neuronale et neuroendocrine (DC2N), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroendocrinologie cellulaire et moléculaire, and Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,Oncology ,Hydrocortisone ,MESH: Carcinoma, Neuroendocrine ,Somatic cell ,Endocrinology, Diabetes and Metabolism ,Cushing's syndrome ,Vandetanib ,MESH: Cushing Syndrome ,0302 clinical medicine ,Endocrinology ,Piperidines ,medullary thyroid carcinoma ,[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB] ,MESH: Protein Kinase Inhibitors ,Cushing Syndrome ,MESH: Middle Aged ,Cytoreduction Surgical Procedures ,Middle Aged ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Debulking ,MESH: Hydrocortisone ,3. Good health ,MESH: Quinazolines ,MESH: Piperidines ,MESH: Thyroid Neoplasms ,030220 oncology & carcinogenesis ,Thyroidectomy ,Neck Dissection ,Tyrosine kinase ,Long term control ,medicine.drug ,Calcitonin ,medicine.medical_specialty ,vandetanib ,Medullary cavity ,030209 endocrinology & metabolism ,MESH: Proto-Oncogene Proteins c-ret ,MESH: Thyroidectomy ,Thyroid carcinoma ,03 medical and health sciences ,Internal medicine ,MESH: Neck Dissection ,medicine ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Humans ,MESH: Cytoreduction Surgical Procedures ,Thyroid Neoplasms ,Protein Kinase Inhibitors ,MESH: Humans ,hypercortisolism ,MESH: Calcitonin ,business.industry ,Proto-Oncogene Proteins c-ret ,MESH: Male ,Carcinoma, Neuroendocrine ,Quinazolines ,business ,RET - Abstract
Medullary thyroid carcinomas (MTCs) complicated by ectopic Cushing's syndrome (CS) have a poor prognosis, partially due to the difficulty in controlling hypercortisolism by adrenal blocking drugs. Recent reports (including the initial follow-up of this patient) have suggested that tyrosine kinase inhibitors (TKIs) may be a therapeutic option due to an anti-secretory action on ACTH. However, there is a lack of long-term follow-up studies.The case is reported of a 58-year-old man with MTC-related CS resistant to a combination of several anti-cortisolic drugs. Vandetanib, an oral multi-TKI that targets RET in particular, was initiated, and a rapid reversal of the hypercortisolism was observed without any change in tumor size. Vandetanib was briefly interrupted twice, once for 45 days because of side effects and a second time for 10 days to schedule surgical debulking. Each time, plasma cortisol and calcitonin levels increased after TKI withdrawal and were rapidly lowered by vandetanib reintroduction. As described in other cases of CS caused by MTC, a marked ACTH increase after desmopressin stimulation was observed before vandetanib therapy. In contrast, a blunted ACTH response to desmopressin was documented throughout the course of vandetanib treatment. This modulation of the tumoral ACTH production is a strong argument in favor of a TKI anti-secretory action. A left thyroid lobectomy and a modified neck dissection were performed one year after the initiation of vandetanib in order to reduce the tumor mass. An activating M918T RET (c.2753TC) somatic mutation was identified in a lymph node metastasis.Three years and eight months after vandetanib initiation, there was no sign of recurrence of hypercortisolism. This case illustrates the long-term effectiveness of vandetanib in maintaining the control of hypercortisolism in MTC-related CS.
- Published
- 2017
- Full Text
- View/download PDF
41. DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer
- Author
-
Anne, Jouinot, Guillaume, Assie, Rossella, Libe, Martin, Fassnacht, Thomas, Papathomas, Olivia, Barreau, Bruno, de la Villeon, Simon, Faillot, Nadim, Hamzaoui, Mario, Neou, Karine, Perlemoine, Fernande, Rene-Corail, Stéphanie, Rodriguez, Mathilde, Sibony, Frédérique, Tissier, Bertrand, Dousset, Silviu, Sbiera, Cristina, Ronchi, Matthias, Kroiss, Esther, Korpershoek, Ronald, de Krijger, Jens, Waldmann, Detlef, K, Bartsch, Marcus, Quinkler, Magalie, Haissaguerre, Antoine, Tabarin, Olivier, Chabre, Nathalie, Sturm, Michaela, Luconi, Franco, Mantero, Massimo, Mannelli, Regis, Cohen, Véronique, Kerlan, Philippe, Touraine, Gaelle, Barrande, Lionel, Groussin, Xavier, Bertagna, Eric, Baudin, Laurence, Amar, Felix, Beuschlein, Eric, Clauser, Joel, Coste, Jérôme, Bertherat, Pathology, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), CHU Cochin [AP-HP], Department of Psychiatry, Chirurgie digestive, hépato-biliaire et endocrinienne [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München (LMU), Comprehensive Cancer Center Mainfranken, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Department of Pathology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Clinical Genetics, Département d'endocrinologie - Bordeaux 2, Université Bordeaux Segalen - Bordeaux 2, Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL), Laboratoire de Cytologie, Département d'Anatomie et de Cytologie Pathologiques, CHU Grenoble-Hôpital Michallon, Department of Endocrinology and Diabetes Mellitus, Hôpital Delafontaine, Service d'Endocrinologie (CHRU - Endocrino), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Département d'endocrinologie et Médecine Reproductive [AP-HP Hôpital Pitié-Salpétrière], AP-HP Hôpital Universitaire Pitié Salpêtrière - GHU Pitié Salpêtrière, Centre Hospitalier Régional d'Orléans (CHR), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Université de Brest (UBO)-Université de Brest (UBO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional d'Orléans (CHRO), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
- Subjects
0301 basic medicine ,Male ,[SDV]Life Sciences [q-bio] ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,medical ,Biochemistry ,0302 clinical medicine ,Endocrinology ,Adrenocortical Carcinoma ,Methylation ,DNA, Neoplasm ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Middle Aged ,Prognosis ,3. Good health ,Tumor Burden ,Diabetes and Metabolism ,Survival Rate ,CpG site ,030220 oncology & carcinogenesis ,Cohort ,DNA methylation ,Female ,Adult ,medicine.medical_specialty ,Context (language use) ,Biology ,Disease-Free Survival ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Journal Article ,Humans ,Survival rate ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Biochemistry, medical ,Proportional hazards model ,Biochemistry (medical) ,Retrospective cohort study ,DNA Methylation ,Adrenal Cortex Neoplasms ,030104 developmental biology ,Ki-67 Antigen ,Multivariate Analysis ,CpG Islands ,Multiplex Polymerase Chain Reaction ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Context:Adrenocortical cancer (ACC) is an aggressive tumor with a heterogeneous outcome. Prognostic stratification is difficult even based on tumor stage and Ki67. Recently integrated genomics studies have demonstrated that CpG islands hypermethylation is correlated with poor survival.Objective:The goal of this study was to confirm the prognostic value of CpG islands methylation on an independent cohort.Design:Methylation was measured by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA).Setting:MS-MLPA was performed in a training cohort of 50 patients with ACC to identify the best set of probes correlating with disease-free survival (DFS) and overall survival (OS). These outcomes were validated in an independent cohort from 21 ENSAT centers.Patients:The validation cohort included 203 patients (64% women, median age 50 years, 80% localized tumors).Main Outcome Measures:DFS and OS.Results:In the training cohort, mean methylation of 4 genes (PAX5, GSTP1, PYCARD, PAX6) was the strongest methylation marker. In the validation cohort, methylation was a significant prognostic factor of DFS (P < 0.0001) and OS (P < 0.0001). Methylation, Ki67, and ENSAT stage were combined in multivariate models. For DFS, methylation (P = 0.0005) and stage (P < 0.0001) but not Ki67 (P = 0.19) remained highly significant. For OS, methylation (P = 0.0006), stage (P < 0.0001), and Ki67 (P = 0.024) were independent prognostic factors.Conclusions:Tumor DNA methylation emerges as an independent prognostic factor in ACC. MS-MLPA is readily compatible with clinical routine and should enhance our ability for prognostication and precision medicine.
- Published
- 2017
- Full Text
- View/download PDF
42. Épi-Hypo : état des lieux de l’hypoparathyroïdie en France
- Author
-
Justine Bacchetta, I. Epi-Hypo, Agnès Linglart, Gérard Maruani, Lionel Groussin, Pascal Houillier, Peter Kamenicky, O. Tabarin, J.P. Riveline, Jean-Philippe Bertocchio, Caroline Silve, T. Brue, L. Crinière, Jean-Philippe Haymann, and Marie-Christine Vantyghem
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Introduction L’hypoparathyroidie est une secretion insuffisante d’hormone parathyroidienne entrainant une hypocalcemie. Les causes sont chirurgicales, genetiques, auto-immunes, infiltratives, voire « idiopathique ». Les complications peuvent etre fonctionnelles (neuro/musculaires) et/ou par des calcifications des tissus. Les diagnostics et prises en charge impliquent differentes specialites, et il n’existe pas de donnees nationales francaises. Notre objectif est de faire un etat des lieux de l’hypoparathyroidie chronique en France. Methodes Une plateforme de saisie en ligne a permis de collecter anonymement les donnees cliniques et biologiques des patients au diagnostic et au cours du suivi. La plupart des professionnels impliques a ete contacte depuis septembre 2016 via le centre de reference des maladies rares du calcium et du phosphate (OSCAR) et la SFE. Resultats Au 31 mars 2018, 745 patients etaient inclus (femmes : 71 % ; mineurs : 12 %). Le delai entre le premier symptome et le diagnostic etait de 0 a 77 ans. Les causes au moment de l’inclusion etaient chirurgicale (71 %), genetique (9 %), auto-immune (3 %), radiotherapie (1 %) ou non identifiee (16 %). Au diagnostic, la calcemie etait mesuree a 1,80 ± 0,30 mm ; 15 % des patients avaient une insuffisance renale definie par un debit de filtration glomerulaire estime Discussion Epi-Hypo est la premiere etude nationale sur l’hypoparathyroidie. Elle a probablement un biais de recrutement (centres experts) et va etre completee pour refleter la diversite des situations, preciser la prevalence des complications et identifier des pistes d’amelioration dans la prise en charge. Cependant, Epi-Hypo confirme l’importante prevalence des complications renales de l’hypoparathyroidie.
- Published
- 2018
- Full Text
- View/download PDF
43. Stabilité des marqueurs moléculaires des corticosurrénalomes face à l’hétérogénéité intra-tumorale
- Author
-
Rossella Libé, Lionel Groussin, B. De La Villéon, Jérôme Bertherat, Anne Jouinot, Sébastien Gaujoux, Mario Neou, Guillaume Assié, Bertrand Dousset, Karine Perlemoine, Simon Garinet, and Mathilde Sibony
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Les corticosurrenalomes ont un pronostic heterogene. Recemment, les etudes de genomique ont identifie 3 sous-groupes de tumeurs caracterises par des alterations moleculaires specifiques. La classification moleculaire peut etre determinee en routine par des marqueurs cibles et ameliore l’evaluation du pronostic. Objectif Evaluer l’heterogeneite intra-tumorale des alterations moleculaires. Patients et methodes Analyse des mutations de 20 genes drivers (NGS cible) et des alterations chromosomiques (puces SNP) dans 2 echantillons tumoraux differents pour 14 patients operes d’un corticosurrenalome : primitif et metastase (n = 9 dont 5 atteintes metachrones), 2 echantillons de volumineux primitif (n = 2) ou 2 echantillons de metastases (n = 3). Resultats Nous avons observe entre 0 et 4 alterations par echantillon parmi les 20 genes drivers, notamment ZNRF3 (25 %), TP53 (21 %), CTNNB1 (18 %), CDKN2A (21 %) et TERT (21 %). Certaines alterations (CDKN2A, CTNNB1, ZNRF3) n’etaient presentes que dans une metastase (n = 3) ou dans un des deux echantillons du primitif (n = 1). L’heterogeneite intra-tumorale n’etait pas associee au stade au diagnostic ou au grade tumoral. Nous avons identifie des profils d’alterations chromosomiques « bruite » (nombreuses cassures anarchiques) pour 67 % et « chromosomal » (pertes d’heterozygotie etendues) pour 33 % des echantillons, similaires pour les 2 echantillons de chaque patient. Discussion Pour 4/14 patients, l’heterogeneite des mutations somatiques evoque la presence de sous-clones tumoraux d’agressivite differente. Cependant, le profil global des alterations chromosomiques reste identique, suggerant une stabilite genetique lors de la progression tumorale dans les corticosurrenalomes par comparaison a d’autres cancers.
- Published
- 2018
- Full Text
- View/download PDF
44. Genetic evaluation in primary hyperparathyroidism: What investigation? For which patients?
- Author
-
Lionel Groussin
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,General Medicine ,Hyperparathyroidism, Primary ,medicine.disease ,Diagnosis, Differential ,Endocrinology ,Internal medicine ,Hypercalcemia ,Multiple Endocrine Neoplasia Type 1 ,medicine ,Humans ,business ,Primary hyperparathyroidism - Published
- 2015
- Full Text
- View/download PDF
45. Molecular perspectives in differentiated thyroid cancer
- Author
-
C. Buffet and Lionel Groussin
- Subjects
medicine.medical_specialty ,Telomerase ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Biology ,medicine.disease_cause ,Targeted therapy ,Phosphatidylinositol 3-Kinases ,Endocrinology ,Molecular genetics ,Adenocarcinoma, Follicular ,medicine ,Anaplastic lymphoma kinase ,Humans ,Telomerase reverse transcriptase ,Thyroid Neoplasms ,Thyroid cancer ,Thyroid ,Carcinoma ,GTPase-Activating Proteins ,General Medicine ,medicine.disease ,Prognosis ,Carcinoma, Papillary ,medicine.anatomical_structure ,Thyroid Cancer, Papillary ,Mutation ,Cancer research ,Mitogen-Activated Protein Kinases ,Carcinogenesis ,Signal Transduction - Abstract
Progress in understanding the molecular genetics of thyroid cancer in the last 20 years has accelerated recently with the advent of high-throughput sequencing technologies known as Next-Generation Sequencing. Besides classical molecular abnormalities involving the MAPK (Mitogen Activated Protein Kinase) and PI3K (PhosphoInositide 3-Kinase) pathways that play a key role in follicular-derived thyroid tumorigenesis, new molecular abnormalities have been discovered. The major advances in recent years have been the discovery of new somatic driver gene point mutations (such as RASAL1 [RAS protein activator Like 1] mutations in follicular cancer) and/or mutations that have prognostic value (such as TERT [Telomerase reverse transcriptase] promoter mutations); new chromosomal rearrangements, usually having close connection with exposure to ionizing radiation (such as ALK [Anaplastic Lymphoma Kinase] rearrangements); and deregulation of some gene or microRNA expression representing a molecular signature. Progress made in understanding the molecular mechanisms of thyroid cancer offers new perspectives for the diagnosis of the benign or malignant status of a thyroid nodule, to refine prognosis and offer new perspectives of targeted therapy for radioiodine-refractory cancers.
- Published
- 2016
46. Outpatient Thyroid Remnant Ablation Using Repeated Low 131-Iodine Activities (740 MBq/20 mCi × 2) in Patients with Low-Risk Differentiated Thyroid Cancer
- Author
-
Thierry Delbot, Alain Chevalier, Marie Bienvenu-Perrard, Caroline Pichard de Malleray, Lionel Groussin, Jérôme Clerc, Robert J. Marlowe, Françoise Aubène Leger, F. Dagousset, and Marc Dreyfuss
- Subjects
Adult ,Male ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Urinary system ,Clinical Biochemistry ,chemistry.chemical_element ,Context (language use) ,Iodine ,Scintigraphy ,Biochemistry ,Endocrinology ,Internal medicine ,Adenocarcinoma, Follicular ,Ambulatory Care ,medicine ,Humans ,Postoperative Period ,Thyroid Neoplasms ,Thyroid cancer ,Aged ,Retrospective Studies ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Biochemistry (medical) ,Thyroid ,Middle Aged ,Ablation ,medicine.disease ,Adenocarcinoma, Papillary ,Treatment Outcome ,medicine.anatomical_structure ,chemistry ,Female ,Thyroglobulin ,business ,Follow-Up Studies - Abstract
In low-risk differentiated thyroid cancer (DTC), postoperative (131)I remnant ablation should employ a minimum effective activity; reports increasingly suggest efficacy of low activities, e.g. 1110 MBq/30 mCi. OBJECTIVES, DESIGN, PATIENTS, AND INTERVENTIONS: We retrospectively studied the ablation capability and diagnostic utility of the Minidose protocol, two 740-MBq/20 mCi outpatient administrations, 6-18 months apart, plus related diagnostic procedures, in 160 consecutive (near-) totally thyroidectomized low-risk DTC (pT1/N0-Nx) patients. Successful ablation comprised negative 740-MBq whole-body scintigraphy with cervical uptake below 0.1%, negative stimulated thyroglobulin (STg) (1 ng/ml, negative thyroglobulin antibodies), and negative Doppler ultrasonography (performed around Minidose 2).The study took place at a referral center.Minidose imaging found unsuspected nodal or distant metastases in nine of 160 patients (5.6%). Ablation success rates after one (two) 740-MBq activity (activites) were 75.9% (90.2%) in 145 (132) evaluable imaging-negative patients. Compared with thyroid hormone withdrawal, recombinant human TSH stimulation was associated with higher urinary iodine excretion/creatinine, lower cervical uptake, and more frequent ablation success after the first 740 MBq; success rates no longer differed significantly after both administrations. Patients with STg below 10 ng/ml at Minidose 1 were oftener ablated at Minidose 2 (odds ratio=13.9, 95% confidence interval=2.5-76.4, P0.003), attaining 92.0% final ablation success after recombinant human TSH preparation, suggesting that one 740-MBq activity should suffice in this subgroup. All 81 evaluable patients with prolonged follow-up (mean 41.8±21.9 months after Minidose 1) had no evidence of disease at the last visit.The Minidose outpatient ablation protocol is effective and diagnostically useful in low-risk DTC.
- Published
- 2012
- Full Text
- View/download PDF
47. Insuffisance thyréotrope au cours du traitement des adénomes thyréotropes par les analogues de la somatostatine (SMSa) de première génération : à propos de 5 observations
- Author
-
P. Caron, Lionel Groussin, Véronique Kerlan, Frédéric Illouz, and S. Baudin
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Le traitement de premiere intention des adenomes thyreotropes est l’adenomectomie chirurgicale. Une alternative therapeutique repose sur les SMSa de premiere generation (sandostatine, lanreotide) et l’apparition d’une insuffisance thyreotrope est rare au cours de ce traitement. Nous rapportons les donnees clinico-bio-radiologiques de cinq patientes (31 a 54 ans) presentant un adenome thyreotrope (TSH = 7,1 ± 7,3 mUI/L, T4L = 36 ± 7,7 pmol/L, T3L = 13,7 ± 3,3 pmol/L ; macro-adenome : n = 4), et ayant developpe une insuffisance thyreotrope isolee au cours du traitement par octreotide (n = 3, 30 mg ou 20 mg/28 jours) ou lanretotide (n = 2, 60 ou 90 mg/28 jours). L’insuffisance thyreotrope apparait precocement apres la premiere (n = 3, 12 a 30 jours), ou la seconde injection (n = 1, 60 jours), avec une diminution de TSH (9,2 ± 8,3 a 0,27 ± 0,23 mUI/L), de T4l (35,8 ± 8,3 a 10,1 ± 1,5 pmol/L) et de T3l (14,1 ± 3,8 a 2,5 ± 0,9 pmol/L). Chez 2 patientes, la surveillance IRM note une diminution du volume adenomateux. La derniere patiente presente un macro-adenome a TSH/GH et l’insuffisance thyreotrope apparait lors d’un traitement prolonge par SMSa lorsque la posologie est augmentee pour controler l’hypersecretion somatotrope (TSH : 5 a 3,8 mUI/L, T4l : 31 a 10,6 pmol/L ; T3l : 13,1 a 3,2 pmol/L). Au total, une insuffisance thyreotrope peut apparaitre au cours du traitement des adenomes thyreotropes par les SMSa. Elle peut etre precoce et etre un facteur predictif de la reponse hormonale et morphologique. Du point de vue therapeutique, elle peut imposer l’adaptation de la posologie des SMSa ou un traitement substitutif par levothyroxine.
- Published
- 2017
- Full Text
- View/download PDF
48. Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused byPRKAR1AMutations:PDE11AMay Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype
- Author
-
Maria Nesterova, Xavier Bertagna, Anelia Horvath, Bruno Ragazzon, Jérôme Bertherat, Delphine Vezzosi, Eric Clauser, Joël Coste, Marine Guillaud-Bataille, Fabio R. Faucz, Limor Drori-Herishanu, Jason Moran, Marie-Laure Raffin-Sanson, Lionel Groussin, Rossella Libé, Constantine A. Stratakis, Karine Perlemoine, Maya Lodish, Amato Fratticci, and Jennifer Siegel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Cyclic AMP-Dependent Protein Kinase RIalpha Subunit ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Adrenal Gland Neoplasm ,Adrenal Gland Neoplasms ,Biology ,medicine.disease_cause ,Biochemistry ,Germline ,Sex Factors ,Endocrinology ,Testicular Neoplasms ,3',5'-Cyclic-GMP Phosphodiesterases ,Internal medicine ,medicine ,Humans ,RNA, Small Interfering ,Carney Complex ,Child ,PRKAR1A ,Carney complex ,Mutation ,Phosphoric Diester Hydrolases ,Biochemistry (medical) ,Genetic Variation ,Middle Aged ,medicine.disease ,Phenotype ,HEK293 Cells ,Child, Preschool ,Sertoli Cell Tumor ,Original Article ,Female ,Primary pigmented nodular adrenocortical disease - Abstract
Carney complex (CNC) is an autosomal dominant multiple neoplasia, caused mostly by inactivating mutations of the regulatory subunit 1A of the protein kinase A (PRKAR1A). Primary pigmented nodular adrenocortical disease (PPNAD) is the most frequent endocrine manifestation of CNC with a great inter-individual variability. Germline, protein-truncating mutations of phosphodiesterase type 11A (PDE11A) have been described to predispose to a variety of endocrine tumors, including adrenal and testicular tumors.Our objective was to investigate the role of PDE11A as a possible gene modifier of the phenotype in a series of 150 patients with CNC.A higher frequency of PDE11A variants in patients with CNC compared with healthy controls was found (25.3 vs. 6.8%, P0.0001). Among CNC patients, those with PPNAD were significantly more frequently carriers of PDE11A variants compared with patients without PPNAD (30.8 vs. 13%, P = 0.025). Furthermore, men with PPNAD were significantly more frequently carriers of PDE11A sequence variants (40.7%) than women with PPNAD (27.3%) (P0.001). A higher frequency of PDE11A sequence variants was also found in patients with large-cell calcifying Sertoli cell tumors (LCCSCT) compared with those without LCCSCT (50 vs. 10%, P = 0.0056). PDE11A variants were significantly associated with the copresence of PPNAD and LCCSCT in men: 81 vs. 20%, P0.004). The simultaneous inactivation of PRKAR1A and PDE11A by small inhibitory RNA led to an increase in cAMP-regulatory element-mediated transcriptional activity under basal conditions and after stimulation by forskolin.We demonstrate, in a large cohort of CNC patients, a high frequency of PDE11A variants, suggesting that PDE11A is a genetic modifying factor for the development of testicular and adrenal tumors in patients with germline PRKAR1A mutation.
- Published
- 2011
- Full Text
- View/download PDF
49. Prise en charge des récidives des hyperparathyroïdies
- Author
-
Lionel Groussin
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
La chirurgie permet dans plus de 95 % des cas d’obtenir une guerison de l’hyperparathyroidie primaire. Dans le cas contraire ou en cas de recidive, la prise en charge necessite une approche methodique. La premiere etape est de s’assurer de la recidive d’un point de vue biologique. L’absence de guerison apres l’exerese d’une glande parathyroidienne pathologique (adenome ou hyperplasie) est en faveur d’une maladie pluri-glandulaire, ce qui conduit a evoquer la possibilite d’une susceptibilite genetique, en raison de l’impact sur l’indication (mutation du recepteur du calcium…) ou la strategie de reprise chirurgicale. Si l’indication operatoire reste formelle (retentissement, severite…), l’enjeu sera alors de determiner avec la plus grande confiance la localisation du tissu parathyroidien pathologique pour optimiser les chances de guerison. Parmi les examens a visee topographique, l’echographie cervicale realisee par un operateur expert, couplee a la scintigraphie au MIBI (avec des tomographies et de l’imagerie de fusion), restent des examens pratiques dans cette indication, mais actuellement concurrencer par le developpement de la prometteuse scintigraphie TEP a la choline. L’imagerie en coupes par scanner ou resonnance magnetique gardent des indications en complement de la scintigraphie, notamment pour les localisations ectopiques. Les progres actuels et a venir de la scintigraphie vont peut-etre conferer une place encore plus limitee a l’exploration par catheterisme pour realiser des dosages etages de PTH. Dans les situations ou la chirurgie ne peut etre envisagee par absence d’imagerie concluante ou en cas d’echec d’une reprise chirurgicale, un traitement medicamenteux par calcimimetique est la strategie a envisager.
- Published
- 2018
- Full Text
- View/download PDF
50. Génomique intégrée des lésions corticosurrénaliennes bénignes
- Author
-
Karine Perlemoine, F. Bonnet, Lionel Groussin, L. Drougat, Anne Jouinot, Jean Guibourdenche, Mathilde Sibony, Bruno Ragazzon, Jérôme Bertherat, W. Luscap Rondof, A. De Reyniès, Guillaume Assié, Bertrand Dousset, M. Rizk Rabin, Rossella Libé, Amandine Septier, Simon Garinet, Anna Vaczlavik, S. Faillot, Stéphanie Espiard, Frédérique Tissier, and Mario Neou
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Les lesions corticosurrenaliennes benignes regroupent un large eventail de maladies avec des morphologies ainsi que des secretions de steroides distinctes. Contrairement au corticosurrenalome, aucune vision globale moleculaire des alterations moleculaires n’est disponible pour ces tumeurs. Objectifs Fournir une classification moleculaire des tumeurs corticosurrenaliennes benignes, en utilisant une serie de mesures non biaisees pan-genomiques dans une cohorte incluant tous les types de tumeurs corticosurrenaliennes benignes. Methodes L’etude effectuee rapporte l’analyse pan-genomique incluant transcriptome, miRNome, methylome, mutations et alterations chromosomiques de 146 lesions adrenocorticales benignes. Resultats Le transcriptome, le methylome, le miRNome et le statut mutationnel convergent en une seule classification avec quatre groupes principaux : (i) les tumeurs productrices de cortisol, regroupant differents types partageant une activation commune de la voie AMPc/PKA par des mecanismes distincts. Le transcriptome a permis d’identifier une signature steroidogene ; (ii) des adenomes corticosurrenaliens (ACA) sans ou avec une secretion legere de cortisol, associes a des mutations de la beta-catenine ; (iii) des hyperplasies macronodulaires primaires avec des mutations ARMC5, montrant une signature d’expression ovarienne ; (iv) des ACA produisant de l’aldosterone, en dehors d’autres tumeurs benignes. Les alterations epigenetiques et la steroidogenese semblent associees, incluant l’hypomethylation des ilots CpG dans les tumeurs sans ou avec une secretion legere de cortisol, les profils des miARN definissant des groupes moleculaires specifiques, et la regulation directe de l’expression des enzymes steroidogenes par la methylation. Conclusion Cette premiere caracterisation pan-genomique a grande echelle des lesions corticosurrenaliennes benignes represente une nouvelle ressource importante pour l’etude de la tumorigenese corticosurrenalienne et de la steroidogenese.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.